Can I take Willow Bark with Sulindac?
Oral willow bark products with oral sulindac 150 or 200 mg tablets. Medicinal Salix bark guidance has defined preparation scope; exact species and salicin content must be checked.
Read the interaction guide →Find an answer about a specific supplement and medication. Browse by medication or explore the available combination guides.
1161 published guides. Coverage is limited to the combinations listed.
Oral willow bark products with oral sulindac 150 or 200 mg tablets. Medicinal Salix bark guidance has defined preparation scope; exact species and salicin content must be checked.
Read the interaction guide →Oral garlic supplements with oral sulindac 150 or 200 mg tablets. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable.
Read the interaction guide →Oral Panax ginseng with oral sulindac 150 or 200 mg tablets. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable.
Read the interaction guide →Oral ginger root powder with oral sulindac 150 or 200 mg tablets. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable.
Read the interaction guide →Specified oral Harpagophytum procumbens root preparations with oral sulindac 150 or 200 mg tablets. The monograph also covers H. zeyheri; species and extract must be checked.
Read the interaction guide →Oral Ginkgo biloba with oral sulindac 150 or 200 mg tablets. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable.
Read the interaction guide →Oral potassium replacement with oral sulindac 150 or 200 mg tablets. Potassium chloride solution evidence supplies a regulatory class bridge; dietary potassium and other routes are separate.
Read the interaction guide →Oral Hypericum perforatum extract and oral temazepam; different benzodiazepine metabolic pathways remain distinct.
Read the interaction guide →Radix et Rhizoma Valerianae species unresolved; V. officinalis evidence applies only if the product matches.
Read the interaction guide →Oral Piper methysticum products; extract, dose and additional sedatives matter.
Read the interaction guide →Oral Humulus lupulus female inflorescence preparations; other parts and mixed products are not assumed equivalent.
Read the interaction guide →Oral caffeine and temazepam for short-term insomnia; stimulant sleep effects are distinct from reduced drug absorption.
Read the interaction guide →Oral Passiflora incarnata aerial-part preparations, not another species or every extract.
Read the interaction guide →Oral melatonin; prolonged-release product guidance and immediate-release experimental doses are not identical.
Read the interaction guide →Oral Melissa officinalis leaf preparations; other parts and mixed products are not assumed equivalent.
Read the interaction guide →German chamomile, Matricaria chamomilla/re-cutita synonym, specified oral extract; not Roman chamomile or every tea/plant part.
Read the interaction guide →Oral Curcuma longa (turmeric) with adult oral dabigatran etexilate capsules. Whole turmeric, concentrated curcumin and enhanced-absorption mixtures are distinct.
Read the interaction guide →Oral vitamin E supplements with adult oral dabigatran etexilate. Food intake, natural/synthetic alpha-tocopherol and other vitamin E forms are not assigned identical risks.
Read the interaction guide →Oral Allium sativum supplements with adult oral dabigatran etexilate; aged extract, powders and oils are not assumed equivalent. Culinary use is a separate exposure.
Read the interaction guide →Oral Hypericum perforatum (St. John’s wort) products with adult oral dabigatran etexilate; exact extract composition varies.
Read the interaction guide →Oral Panax ginseng with adult oral dabigatran etexilate capsules. American ginseng, other species and multi-herb formulas are not treated as equivalent.
Read the interaction guide →Oral Zingiber Officinale (Ginger) Root Powder with adult oral dabigatran etexilate. Powder, extracts, food portions and the reported mixed ginger/cinnamon decoction are not interchangeable.
Read the interaction guide →Oral fish oil supplements containing EPA/DHA with adult oral dabigatran etexilate. Pure EPA prescription products, other omega-3 sources and combination products require separate assessment.
Read the interaction guide →Oral magnesium carbonate with intact adult oral dabigatran etexilate capsules. Other magnesium salts, proton-pump inhibitors and experimental tablets are separate exposures.
Read the interaction guide →Oral Ginkgo biloba products with adult oral dabigatran etexilate; leaf extracts are distinguished from seeds, other plant parts and mixed products.
Read the interaction guide →Oral Tanacetum parthenium (feverfew) supplements with adult oral dabigatran etexilate capsules; extract, leaf and high-dose preparations may differ.
Read the interaction guide →Oral tetracycline hydrochloride and oral Angelica sinensis root preparations. Skin contact with a mixed decoction is a separate exposure; other Angelica species are not merged.
Read the interaction guide →Oral tetracycline hydrochloride and oral iron; ferrous sulfate is the directly studied form. Intravenous iron is not assessed by this digestive-tract interaction.
Read the interaction guide →Oral tetracycline hydrochloride and oral Hypericum perforatum extracts. LI 160 studies are ingredient-only evidence, not a direct combination trial; pure hypericin and topical products are distinct.
Read the interaction guide →Oral tetracycline hydrochloride and potassium citrate, including prescription extended-release potassium citrate. Calcium citrate, sodium bicarbonate and other antibiotics remain separate exposures.
Read the interaction guide →Oral calcium citrate and tetracycline hydrochloride capsules. Application of general calcium-supplement guidance to citrate is explicit; no citrate-specific human absorption result is claimed.
Read the interaction guide →Oral tetracycline hydrochloride with magnesium-containing antacids or laxatives. The direct experiment used a combined magnesium/aluminum hydroxide gel; other nutritional salts have limited exact evidence.
Read the interaction guide →Oral tetracycline hydrochloride and zinc products; the direct trial tested zinc sulfate providing 45 mg zinc. Doxycycline is distinct and showed a different result in the same paper.
Read the interaction guide →Oral tetracycline hydrochloride capsules with calcium-containing antacids or supplements. Calcium salt and dose are retained; the effect of every formulation is not quantified.
Read the interaction guide →Oral thioridazine with the exact supplement preparation described.
Read the interaction guide →Oral thioridazine with the exact supplement preparation described.
Read the interaction guide →Oral thioridazine with the exact supplement preparation described.
Read the interaction guide →Oral thioridazine with the exact supplement preparation described.
Read the interaction guide →Oral thioridazine with the exact supplement preparation described.
Read the interaction guide →Oral thioridazine with the exact supplement preparation described.
Read the interaction guide →Oral thiothixene with the exact supplement preparation described.
Read the interaction guide →Oral thiothixene with the exact supplement preparation described.
Read the interaction guide →Oral thiothixene with the exact supplement preparation described.
Read the interaction guide →Oral thiothixene with the exact supplement preparation described.
Read the interaction guide →Oral thiothixene with the exact supplement preparation described.
Read the interaction guide →Oral thiothixene with the exact supplement preparation described.
Read the interaction guide →Applies to intravenous or subcutaneous epoetin alfa; the concern is its effect on red blood cell production, not absorption of the injected medicine.
Read the interaction guide →Applies to calcium carbonate with oral levothyroxine tablets or capsules, with direct label evidence from levothyroxine-sodium tablets.
Read the interaction guide →Evidence concerns oral levothyroxine tablets, principally with ferrous sulfate; injectable levothyroxine is outside this finding.
Read the interaction guide →Applies to systemic levothyroxine replacement, with the supporting product evidence centered on oral preparations.
Read the interaction guide →The selected entry groups Laminaria/Ecklonia thallus terminology and does not identify a single species, extract or iodine dose. Evidence below concerns iodine-containing seaweed products, with no confirmed exact-product interaction study.
Read the interaction guide →Oral vitamin C with oral levothyroxine in selected patients with poor control or high dose requirements. Findings do not establish a benefit for all treated patients, every vitamin-C formulation or intravenous vitamin C.
Read the interaction guide →Oral levothyroxine tablets with oral magnesium products. The label specifically addresses magnesium-containing antacids; the trial tested dissolved aspartate and citrate. It did not test glycinate, all capsules or injected thyroid hormone.
Read the interaction guide →Applies to affected thyroid immunoassays regardless of how levothyroxine is administered; it is a test-interference issue.
Read the interaction guide →Oral levothyroxine with dietary fiber or oral fiber supplements. Wheat bran, psyllium and calcium polycarbophil have different evidence and are not interchangeable exposures.
Read the interaction guide →Applies to iron (II) sulfate, also called ferrous sulfate, with oral levothyroxine tablets or capsules.
Read the interaction guide →Evidence concerns oral levothyroxine tablets with calcium carbonate, citrate or acetate; it does not apply to injected levothyroxine.
Read the interaction guide →Grapefruit juice with oral levothyroxine tablets. Evidence must not be transferred automatically to grapefruit seed extract, peel extracts or an unspecified Citrus paradisi supplement.
Read the interaction guide →Soy-derived oral foods and supplements with oral levothyroxine. Protein drinks, soy-based infant formula and isolated isoflavones are distinguished; Glycine max alone does not identify the preparation.
Read the interaction guide →Applies to mineral-containing multivitamins with oral levothyroxine tablets or capsules; the actual formula controls applicability.
Read the interaction guide →Oral Curcuma longa with oral tolmetin sodium capsules. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable.
Read the interaction guide →Oral vitamin E supplements with oral tolmetin sodium capsules. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable.
Read the interaction guide →Oral garlic supplements with oral tolmetin sodium capsules. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable.
Read the interaction guide →Oral Hypericum perforatum preparations with oral tolmetin sodium capsules. Other medicines and preparations require separate review.
Read the interaction guide →Oral ginger root powder with oral tolmetin sodium capsules. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable.
Read the interaction guide →Sodium bicarbonate used as an oral antacid with tolmetin sodium capsules containing tolmetin-equivalent doses. Dietary bicarbonate and other antacids are separate.
Read the interaction guide →Oral Ginkgo biloba with oral tolmetin sodium capsules. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable.
Read the interaction guide →Hypericum perforatum extracts; product composition differs.
Read the interaction guide →Generic root/rhizome identity; species confirmation needed.
Read the interaction guide →Isolated curcumin versus Curcuma domestica/longa extracts and food turmeric; formulations and absorption enhancers differ.
Read the interaction guide →Piper methysticum beverages and extracts; preparations vary.
Read the interaction guide →Oral L-5-hydroxytryptophan supplements.
Read the interaction guide →Concentrated L-tryptophan supplements, not ordinary dietary protein.
Read the interaction guide →Oral Hypericum perforatum preparations used for mood symptoms with oral MAOI treatment. Other botanical species, topical preparations and specific extract strengths are not assumed to be equivalent.
Read the interaction guide →Oral L-tyrosine supplements with tranylcypromine tablets. Tyrosine is not tyramine, and neither ordinary protein foods nor other amino acids are automatically included.
Read the interaction guide →Oral L-5-hydroxytryptophan with oral tranylcypromine tablets. This does not identify a safe amount, equate 5-HTP with L-tryptophan, or clear a mixed botanical product.
Read the interaction guide →Oral Paullinia cupana seed preparations that contain caffeine. No assumption is made about the caffeine concentration of an unidentified brand, a different plant part or a caffeine-free preparation.
Read the interaction guide →Oral tranylcypromine tablets with caffeine from drinks, tablets, powders or other supplements. The concern depends on total exposure; no universal safe amount has been established for this combination.
Read the interaction guide →Oral Ephedra sinica stem or above-ground preparations containing ephedrine-type alkaloids. The assessment does not equate root preparations, other species, purified ephedrine products or unverified alkaloid-free products.
Read the interaction guide →Oral supplemental S-adenosyl-L-methionine, commonly called SAM-e, with oral tranylcypromine. Different commercial salts and blends are not assumed to have identical exposure, and no safe product-specific dose is established.
Read the interaction guide →Oral supplemental L-tryptophan with oral tranylcypromine. The multiagent case includes clomipramine and is not treated as a clean two-agent experiment; normal dietary protein is a separate question.
Read the interaction guide →Camellia sinensis, particularly oral leaf beverages or preparations containing caffeine. This species-level selection does not identify a particular extract, caffeine content or topical formulation.
Read the interaction guide →Oral Herba Ephedrae products consisting of ephedra herb with ephedrine-type alkaloids. The canonical node is kept separate from Ephedra sinica; species, plant part and alkaloid content remain product-specific.
Read the interaction guide →Oral Hypericum perforatum with immediate-release trazodone; extracts vary in hyperforin content.
Read the interaction guide →Radix et Rhizoma Valerianae species unresolved; V. officinalis evidence is conditional on confirmation.
Read the interaction guide →Withania somnifera; root-only trial extract differs from leaf or mixed preparations.
Read the interaction guide →Oral Piper methysticum; extract, amount and other sedatives are relevant.
Read the interaction guide →Concentrated oral L-5-hydroxytryptophan; distinct from the proprietary Sentra PM formula and unspecified precursor amounts.
Read the interaction guide →Oral melatonin with immediate-release trazodone; sleep-study and product formulations are not interchangeable.
Read the interaction guide →Concentrated oral L-tryptophan, distinct from food protein and hydroxytryptophan-containing mixed preparations.
Read the interaction guide →Oral grapefruit extract; not automatically equivalent to grapefruit juice, seed products or a quantified furanocoumarin preparation.
Read the interaction guide →Grapefruit fruit flesh/segments with oral plain triamcinolone; juice studies and other steroid routes are distinguished.
Read the interaction guide →Oral Glycyrrhiza glabra root preparations containing glycyrrhizin. Deglycyrrhizinated products and topical preparations require separate assessment.
Read the interaction guide →Oral calcium carbonate, distinguished from other antacids, with oral plain triamcinolone.
Read the interaction guide →Hypericum perforatum-containing preparations with oral plain triamcinolone; product composition and systemic exposure matter.
Read the interaction guide →Oral Hydrastis canadensis preparations with oral plain triamcinolone; not an equivalent claim for isolated berberine or injected/topical products.
Read the interaction guide →Dietary or supplemental calcium with prolonged oral plain triamcinolone; other routes require separate assessment.
Read the interaction guide →Potassium intake or supplementation with oral plain triamcinolone; other formulations and emergency replacement are separate questions.
Read the interaction guide →Vitamin D nutrition during prolonged systemic exposure to plain oral triamcinolone; not automatic supplementation for local products.
Read the interaction guide →Dietary or supplemental sodium with plain oral triamcinolone; sodium-containing injection ingredients are not the same exposure.
Read the interaction guide →Dietary protein and oral protein supplements with plain triamcinolone tablets; no transfer to topical or local use.
Read the interaction guide →Oral liothyronine and soy-isoflavone supplements. Soy foods, soybean flour and soy-protein products differ from isolated isoflavones; levothyroxine studies are indirect.
Read the interaction guide →Oral liothyronine sodium tablets with oral iron preparations. The intestinal absorption precaution does not apply to an iron infusion in the same way.
Read the interaction guide →The selected Laminariae Thallus Eckloniae Thallus node includes multiple seaweed identities and preparations. Evidence is limited to iodine-rich products and the named Laminaria japonica exposure; Ecklonia products and iodine-free extracts are not assumed equivalent.
Read the interaction guide →Oral supplemental iodine in a person taking liothyronine. Concern is iodine-related thyroid-gland function, not proven binding of the T3 dose. Nutritional requirements and supervised medical iodine treatment are separate questions.
Read the interaction guide →Oral liothyronine sodium tablets and swallowed magnesium products, particularly magnesium-containing antacids. No assumption that every magnesium salt, dose or injected preparation behaves alike.
Read the interaction guide →Oral liothyronine and added fiber products. Human comparison studies here used levothyroxine with dietary fiber, psyllium or calcium polycarbophil, not administered T3.
Read the interaction guide →Oral liothyronine and exact Lycopus virginicus preparations. Lycopus europaeus, other botanicals, multiherb mixtures and different extraction methods are not interchangeable evidence.
Read the interaction guide →Oral liothyronine and aluminum-containing medicinal antacids. This does not concern metal contact, cookware, trace food exposure or aluminum used in packaging.
Read the interaction guide →Oral liothyronine sodium tablets and oral calcium supplements or calcium-containing antacids. No quantified equivalence across calcium salts; injected calcium and ordinary food portions are outside this assessment.
Read the interaction guide →Oral liothyronine with a specified multivitamin or prenatal formula. The term multivitamin does not identify a uniform dose or mixture; the ingredient list controls applicability.
Read the interaction guide →Oral Hypericum perforatum with trimipramine maleate capsules.
Read the interaction guide →Radix et Rhizoma Valerianae species unresolved; V. officinalis evidence is conditional on confirmation.
Read the interaction guide →Oral Piper methysticum; extract, amount and other sedatives are relevant.
Read the interaction guide →Concentrated oral L-5-HTP; distinct from the other serotonin precursor and ordinary food protein.
Read the interaction guide →Oral Passiflora incarnata herb; not fruit or other species.
Read the interaction guide →Concentrated oral L-tryptophan; distinct from the other serotonin precursor and ordinary food protein.
Read the interaction guide →Radix et Rhizoma Glycyrrhizae: exact species, processed root and glycyrrhizic-acid content unresolved; deglycyrrhizinated products are distinct.
Read the interaction guide →Adult oral rivaroxaban with supplemental vitamin E. High-dose single-ingredient products, multivitamins and vitamin E naturally present in foods are distinct exposures.
Read the interaction guide →Adult oral rivaroxaban with oral Hypericum perforatum, also called St. John’s wort. Direct studies used specified hyperforin-containing extracts; other products cannot be assigned the same numerical effect.
Read the interaction guide →Adult oral rivaroxaban and oral Ginkgo biloba leaf products. Direct research applies to EGb 761 at 240 mg/day, not all extracts, seeds, mixtures or doses.
Read the interaction guide →Oral Curcuma longa with oral ticagrelor tablets. Exact formulation, dose and duration matter; other antiplatelet medicines and other supplement preparations are not interchangeable.
Read the interaction guide →Oral vitamin E supplements with oral ticagrelor tablets. Exact formulation, dose and duration matter; other antiplatelet medicines and other supplement preparations are not interchangeable.
Read the interaction guide →Oral garlic supplements with oral ticagrelor tablets. Exact formulation, dose and duration matter; other antiplatelet medicines and other supplement preparations are not interchangeable.
Read the interaction guide →Oral Hypericum perforatum preparations with oral ticagrelor tablets. Hyperforin content, repeated exposure and the exact drug matter.
Read the interaction guide →Oral ginger root powder with oral ticagrelor tablets. Exact formulation, dose and duration matter; other antiplatelet medicines and other supplement preparations are not interchangeable.
Read the interaction guide →Oral fish oil containing EPA and DHA with oral ticagrelor tablets. Purified EPA prescriptions, ALA and all omega-3 doses are not interchangeable.
Read the interaction guide →Oral Ginkgo biloba with oral ticagrelor tablets. Exact formulation, dose and duration matter; other antiplatelet medicines and other supplement preparations are not interchangeable.
Read the interaction guide →Oral verapamil with grapefruit flesh. The clinical PK studies used juice, while NHS guidance explicitly includes fruit.
Read the interaction guide →Applies to oral verapamil; the study used repeated St. John's wort dosing for 14 days, and effects can vary with the botanical preparation.
Read the interaction guide →Oral verapamil and calcium supplements. Above-normal blood calcium and intravenous calcium treatment for overdose are different exposures from routine oral supplementation.
Read the interaction guide →Oral verapamil with Citrus paradisi fruit or juice. Whole-plant botanical extracts, seed products and essential oils are not assumed equivalent to juice.
Read the interaction guide →Oral verapamil with a multivitamin, prenatal multivitamin or multivitamin/mineral product. No fixed ingredient list or dose is implied by that category.
Read the interaction guide →Oral coenzyme Q10 supplements with oral warfarin. The controlled trial evaluated 100 mg daily; it does not establish equivalence among ubiquinone, ubiquinol or different formulations.
Read the interaction guide →Oral Angelica sinensis preparations with oral warfarin. Other Angelica species, mixed formulas and standardized extracts with different constituents are not assumed to have identical effects.
Read the interaction guide →Oral vitamin E supplementation with oral warfarin. Vitamin E forms and doses differ; a serum vitamin E association is not equivalent to a trial of a particular supplement.
Read the interaction guide →Oral Allium sativum supplements with oral warfarin. Evidence for an aged extract or a tested garlic preparation is not automatically transferable to oils, raw garlic, concentrated extracts or ordinary food portions.
Read the interaction guide →Oral bromelain supplements with oral warfarin. Bromelain is a protease mixture; pineapple foods, injectable experimental doses and topical burn treatments are different exposures.
Read the interaction guide →Oral Hypericum perforatum preparations with oral warfarin. Findings concern systemic repeated exposure; constituent content varies among products and topical use was not studied.
Read the interaction guide →Oral Panax ginseng with oral warfarin. Panax quinquefolius, other Panax species, red versus unprocessed preparations and combination formulas are distinct and are not automatically interchangeable.
Read the interaction guide →Oral Salvia miltiorrhiza root/rhizome preparations with oral warfarin. Compound Danshen dripping pills include additional ingredients and provide indirect, formulation-limited evidence.
Read the interaction guide →Oral Zingiber officinale root powder with oral warfarin. Extracts described by root-equivalent amounts, teas, food portions and essential oils are separate preparations, and direct root-powder evidence is limited.
Read the interaction guide →Oral glucosamine sulfate with oral warfarin, informed by broader glucosamine safety reports. The formulation bridge is precautionary and does not merge sulfate, hydrochloride and chondroitin into one identity.
Read the interaction guide →Oral Hydrastis canadensis preparations with oral warfarin. Isolated berberine or hydrastine, other plants containing these alkaloids and different extract compositions remain distinct exposures.
Read the interaction guide →Oral Vaccinium macrocarpon beverages or supplements with oral warfarin, with quantity and preparation identified. Other Vaccinium species and mixed products are not included automatically.
Read the interaction guide →Oral Ginkgo biloba supplements with oral warfarin. Tested extracts, leaf products and mixed supplements are not assumed to be interchangeable.
Read the interaction guide →Oral Tanacetum parthenium with oral warfarin. American feverfew, Parthenium integrifolium, is a different plant; topical use and isolated parthenolide are separate exposures.
Read the interaction guide →Camellia sinensis beverages or supplements with oral warfarin, with preparation and quantity specified. The imported statement combines tea with vitamin K1 and does not isolate a single exact-pair effect.
Read the interaction guide →Oral multivitamins with oral warfarin, specifically vitamin K1-containing formulations in the direct study. Prenatal products and multivitamins without vitamin K are not assumed to have the same interaction.
Read the interaction guide →Vitamin K1 (phylloquinone/phytonadione) with oral warfarin. Routine food intake, low-dose supplements and clinician-directed reversal are different use cases. Findings are not automatically transferred to vitamin K2 forms.
Read the interaction guide →Applies to Valeriana officinalis preparations used orally; botanical composition and sedative potency vary.
Read the interaction guide →Concentration findings concern purified oral pharmaceutical CBD; unstandardized oils and gummies are not equivalent.
Read the interaction guide →Applies to concurrent oral use; melatonin dose, individual sensitivity, other sedatives and driving or fall risk matter.
Read the interaction guide →Oral iron preparations with oral ibandronate sodium. Intravenous iron and intravenous ibandronate are outside this intestinal co-administration assessment.
Read the interaction guide →Oral magnesium-containing supplements, antacids or laxatives with oral ibandronate tablets. Non-oral magnesium and ibandronate injections are outside this gut-absorption assessment.
Read the interaction guide →Aluminum-containing oral medicines or supplements, especially antacids, with oral ibandronate sodium. Environmental aluminum and topical products are not covered.
Read the interaction guide →Oral calcium with oral ibandronate tablets; calcium adequacy also matters during intravenous ibandronate treatment. Gut absorption interference applies to the oral route.
Read the interaction guide →Vitamin D adequacy and oral supplementation during oral or intravenous ibandronate therapy. The 60-minute window belongs to tablets; calcium-vitamin D products also carry the mineral absorption precaution.
Read the interaction guide →Oral multivitamin and multivitamin-mineral products with oral ibandronate. Ingredient-specific effects depend on the actual formula; a prenatal or bone-health product name is not a chemical identity.
Read the interaction guide →This concerns oral Curcuma longa, commonly called turmeric, with oral aspirin. Whole turmeric, extracts and isolated or specially formulated curcumin are different exposures; a finding for one cannot establish the effect of all the others.
Read the interaction guide →Distinguishes food from high-dose vitamin E supplements and preserves dose and formulation uncertainty. Vitamin E is not recommended here for cardiovascular prevention.
Read the interaction guide →Oral Allium sativum products with oral aspirin. Commercial garlic tablets and studied raw-garlic food doses are described separately. The evidence does not assign the same effect to every extract, oil, cooked-food portion or other Allium species.
Read the interaction guide →Evidence concerns 100 mg/day aspirin versus placebo in older adults. Iron pills, iron salts, and timing were not tested.
Read the interaction guide →This concerns dried Zingiber officinale powder sold as ginger root powder. Medicinal ginger powder is made from the rhizome, an underground stem. This naming bridge does not make extracts, teas, fresh ginger or multi-herb products equivalent to the powder.
Read the interaction guide →Evidence is short-term and mostly higher-dose aspirin. It does not establish a vitamin C requirement for all 81 mg or 100 mg aspirin users.
Read the interaction guide →Oral Ginkgo biloba leaf extracts with oral aspirin. The case involved Ginkoba 50:1 extract; the trials tested EGb 761. Ginkgo seeds, powdered leaf, other extracts and different aspirin doses are not assumed to have equivalent effects.
Read the interaction guide →Oral Tanacetum parthenium, feverfew, with oral aspirin. Powdered above-ground herb, the capsule products used in studies and concentrated extracts are distinct preparations. Evidence for purified parthenolide or other Tanacetum species is not treated as equivalent.
Read the interaction guide →This concerns oral Zingiber officinale, commonly called ginger. Dried powder, fresh ginger, tea and extracts have different study evidence. A report involving ginger extract and several other products cannot establish the effect of all products from this species.
Read the interaction guide →Distinguishes potassium in ordinary foods from supplements, replacement products, and potassium-containing salt substitutes.
Read the interaction guide →The direct study used 650 mg aspirin by mouth every 4 hours for three days, not preventive low-dose aspirin and not folic-acid co-use.
Read the interaction guide →Oral vitamin E supplements with adult oral apixaban. Food intake, natural/synthetic alpha-tocopherol and other vitamin E forms are not assigned identical risks.
Read the interaction guide →Oral Allium sativum supplements with adult oral apixaban; aged extract, powders and oils are not assumed equivalent. Culinary use is a separate exposure.
Read the interaction guide →Oral Hypericum perforatum (St. John’s wort) products with adult oral apixaban; exact extract composition varies.
Read the interaction guide →Oral Zingiber Officinale (Ginger) Root Powder with adult oral apixaban. Powder, extracts, food portions and the reported mixed ginger/cinnamon decoction are not interchangeable.
Read the interaction guide →Oral curcumin supplements with adult oral apixaban. A 1 g/day curcumin case does not represent every turmeric or Curcuma longa preparation.
Read the interaction guide →Oral fish oil supplements containing EPA/DHA with adult oral apixaban. Pure EPA prescription products, other omega-3 sources and combination products require separate assessment.
Read the interaction guide →Oral nattokinase supplements with adult oral apixaban; nattokinase/serrapeptase mixtures and fermented soy foods are distinct exposures.
Read the interaction guide →Oral Ginkgo biloba products with adult oral apixaban; leaf extracts are distinguished from seeds, other plant parts and mixed products.
Read the interaction guide →Oral Zingiber Officinale with adult oral apixaban. Powder, extracts, food portions and the reported mixed ginger/cinnamon decoction are not interchangeable.
Read the interaction guide →Powdered Plantago ovata husk, not whole Plantago afra seed or every mixed-fiber supplement.
Read the interaction guide →Asian Panax ginseng root and specific extracts; not American ginseng or every processed ginseng product.
Read the interaction guide →Oral inner-leaf gel versus latex, whole-leaf and topical aloe; these are not interchangeable preparations.
Read the interaction guide →Oral berberine preparations; extract composition and dose vary.
Read the interaction guide →Cinnamon Dry with Ceylon-cinnamon naming; Cinnamomum zeylanicum extract differs from dried bark and from cassia species.
Read the interaction guide →Gymnema sylvestre leaf extract GS4 versus other extracts, teas and whole-leaf products.
Read the interaction guide →Oral Hypericum perforatum preparations with enzyme-inducing potential; product constituent amounts vary.
Read the interaction guide →Asian Panax ginseng root and specific extracts; not American ginseng or every processed product.
Read the interaction guide →Camellia sinensis leaf extract; catechin amount, caffeine, extraction and dose matter.
Read the interaction guide →Momordica charantia capsules versus food, juice, seed and other extracts.
Read the interaction guide →Dietary sodium versus sodium salts or replacement therapy; no blanket high-salt or sodium-pill recommendation.
Read the interaction guide →Dried Taraxacum officinale root, particularly covered decoction preparations; leaf extracts, fresh juice and other formulations differ.
Read the interaction guide →Pharmacologic oral nicotinic acid, especially extended-release preparations; nutritional doses and nicotinamide differ.
Read the interaction guide →Oral moxifloxacin hydrochloride tablets and oral iron products, with direct study evidence for ferrous sulfate. Intravenous iron and ophthalmic moxifloxacin are not assessed by this interaction.
Read the interaction guide →Oral moxifloxacin tablets and magnesium-containing oral preparations, with direct clinical evidence from a combined magnesium/aluminum antacid. Magnesium deficiency and nonoral replacement are separate questions.
Read the interaction guide →Oral moxifloxacin hydrochloride tablets with aluminum-containing antacids or sucralfate. The exposures are distinguished; no gut-absorption result is assigned to injections or eye drops.
Read the interaction guide →Oral moxifloxacin tablets with oral zinc supplements or zinc-containing multivitamins. No zinc-only human trial was established in the targeted sources; injections and eye drops are outside the oral absorption finding.
Read the interaction guide →Oral willow bark preparations covered by the final EMA Salix cortex monograph, including S. purpurea, S. daphnoides and S. fragilis. The broad Willow Bark identity does not establish a product species, preparation or salicin dose.
Read the interaction guide →Oral Allium sativum supplements. The inspected trial used odor-control tablets; culinary garlic, oils and other extracts are not interchangeable.
Read the interaction guide →Oral Panax ginseng. Panax quinquefolius and other species are excluded. Red, unprocessed and extracted products cannot be treated as equivalent without characterization.
Read the interaction guide →Oral Zingiber officinale dried rhizome powder, often labeled ginger root powder. Extracts, essential oils, fresh food and mixed products are separate preparations.
Read the interaction guide →Oral Ginkgo biloba leaf preparations. Defined dry leaf extract and powdered leaf have separate monograph provisions; seeds and unrelated extracts are excluded.
Read the interaction guide →Oral supplemental potassium, with potassium chloride oral solution as the inspected salt and formulation. Elemental potassium exposure is relevant; formulation-specific doses and adverse effects are not generalized to all salts or ordinary food intake.
Read the interaction guide →This answer concerns oral celecoxib. It distinguishes mixed EPA/DHA fish oil from prescription icosapent ethyl and keeps the original studies' populations and formulations separate. Evidence does not automatically extend to ALA, DPA, krill, algal or multi-ingredient products.
Read the interaction guide →Oral benztropine with the specific preparation described below. Only the solid oral potassium chloride and delayed-transit condition is supported; ordinary foods, other salts, liquids and intravenous replacement are distinct.
Read the interaction guide →Oral benztropine with the specific preparation described below.
Read the interaction guide →Oral benztropine with the specific preparation described below.
Read the interaction guide →Oral benztropine with the specific preparation described below.
Read the interaction guide →Oral benztropine with the specific preparation described below.
Read the interaction guide →Oral benztropine with the specific preparation described below. Only the solid oral potassium chloride and delayed-transit condition is supported; ordinary foods, other salts, liquids and intravenous replacement are distinct.
Read the interaction guide →Oral dolutegravir tablets and oral iron supplements. Direct research used ferrous fumarate, not every iron salt, injected iron or every combination antiretroviral formulation.
Read the interaction guide →Oral Hypericum perforatum products with dolutegravir. Botanical strength can vary, but no extract-specific exemption from the current avoidance advice is established here.
Read the interaction guide →Oral magnesium products with oral dolutegravir. Antacids, laxatives and nutritional supplements are distinguished. No direct magnesium-glycinate clinical experiment was located in this targeted check.
Read the interaction guide →Oral dolutegravir with aluminum-containing antacid or buffered products. The human trial used a mixed aluminum/magnesium antacid, not elemental aluminum or every aluminum compound.
Read the interaction guide →Oral zinc supplements with oral dolutegravir. Zinc-only clinical outcomes are distinguished from laboratory zinc chloride, multivitamin mixtures and studies of other integrase inhibitors.
Read the interaction guide →The selected Charcoal entry does not establish activation, formulation or dose. Evidence about medical activated charcoal is considered indirect for the unspecified product and for dolutegravir specifically.
Read the interaction guide →Oral dolutegravir tablets with calcium supplements. The controlled experiment used calcium carbonate; instructions for calcium antacids and other components of combination HIV tablets must be checked separately.
Read the interaction guide →Oral mineral-containing multivitamins with oral dolutegravir. A multivitamin name does not identify the formula. Plain vitamins without the relevant minerals are not automatically assigned the mineral interaction.
Read the interaction guide →Oral Hypericum perforatum; extract composition and hyperforin content matter.
Read the interaction guide →Radix et Rhizoma Valerianae species unresolved; V. officinalis evidence is conditional on confirmation.
Read the interaction guide →Oral Piper methysticum; extract, amount and other sedatives are relevant.
Read the interaction guide →Concentrated oral L-5-hydroxytryptophan, distinct from tryptophan and whole seed products.
Read the interaction guide →Oral Passiflora incarnata herb preparations; not passionfruit or other Passiflora species.
Read the interaction guide →Oral S-adenosyl-L-methionine, not injected SAMe or dietary methionine.
Read the interaction guide →Concentrated oral L-tryptophan, not normal protein foods or a different precursor.
Read the interaction guide →Oral prescribed mirtazapine; cannabis route, THC/CBD content and formulation must be identified. Smoked THC-rich cannabis is not equivalent to oral hemp products.
Read the interaction guide →Oral Allium sativum supplements; garlic oils, aged extracts, powder, food portions and blends are not interchangeable.
Read the interaction guide →Asian Panax ginseng, including specific root-extract studies; American ginseng is a separate species.
Read the interaction guide →Dried Zingiber officinale rhizome powder, often sold as root powder; not all extracts, oils or isolated gingerols.
Read the interaction guide →Oral berberine ingredient; botanical sources, salts, doses and multi-ingredient products may differ.
Read the interaction guide →Oral DL racemate versus R-alpha-lipoic acid or unspecified ALA preparations; human NPH subcutaneous insulin.
Read the interaction guide →Gymnema sylvestre leaf extract GS4; other extracts, powders and botanical names do not guarantee the same exposure.
Read the interaction guide →Oral niacin, especially pharmacologic nicotinic acid; dietary vitamin B3 and nicotinamide are different exposures.
Read the interaction guide →Glycyrrhiza glabra root extract; glycyrrhizin-depleted trial product differs from ordinary high-glycyrrhizin licorice and other species.
Read the interaction guide →Oral ispaghula/psyllium husk products; older Plantago mucilage is a different preparation. Controlled-release acarbose–orlistat differs from conventional acarbose tablets.
Read the interaction guide →Oral intestinal adsorbent charcoal, generally activated preparations; ordinary nonadsorbent carbon is not assumed equivalent.
Read the interaction guide →Oral Momordica charantia capsules, not every food, juice, seed or extract.
Read the interaction guide →Oral glucose/dextrose for appropriate rescue versus supervised intravenous glucose; sucrose is different.
Read the interaction guide →Fenugreek capsules or traditional seed products; preparation and dose matter. Conventional oral acarbose scope.
Read the interaction guide →Oral pancreatin preparations with carbohydrate-splitting enzymes such as amylase; enzyme composition matters.
Read the interaction guide →Trivalent oral chromium supplements; picolinate study does not represent every salt or industrial hexavalent chromium.
Read the interaction guide →Asian Panax ginseng root and specific extracts; American ginseng is a different species. Exact insulin degludec single-insulin product scope.
Read the interaction guide →Dried Zingiber officinale rhizome powder, sold as root powder; oils and concentrated extracts differ. Exact insulin degludec scope.
Read the interaction guide →Oral berberine; salts, botanical sources and mixtures may differ. Single-ingredient subcutaneous degludec scope.
Read the interaction guide →Glycyrrhizin-containing oral licorice preparations with oral bumetanide tablets. Defined root/stolon preparations are not every processed rhizome, formula or deglycyrrhizinated product.
Read the interaction guide →Oral Panax ginseng products with bumetanide; an older furosemide case involved a germanium-containing mixed exposure.
Read the interaction guide →Magnesium status and replacement during oral bumetanide treatment; healthy short trials differ from long-term illness and PPI co-use.
Read the interaction guide →Oral Herba Taraxaci products with bumetanide. Leaf extract and root-with-herb monograph evidence do not authenticate every aerial-herb preparation.
Read the interaction guide →Oral Equisetum arvense aerial-part products with bumetanide; defined extract evidence is short and healthy-population only.
Read the interaction guide →Oral potassium intake and replacement during oral bumetanide tablets treatment, distinguished from automatic supplementation or intravenous correction.
Read the interaction guide →Oral Juniperus communis preparations with bumetanide; final assessment concerns medicinal cones, not every plant part or essential oil.
Read the interaction guide →Hypericum perforatum oral products; constituent strength differs among preparations.
Read the interaction guide →Generic root and rhizome identity; confirm the species before applying Valeriana officinalis guidance.
Read the interaction guide →Piper methysticum products; beverages and extracts are not interchangeable.
Read the interaction guide →Oral L-5-hydroxytryptophan supplements; not ordinary dietary protein.
Read the interaction guide →Oral melatonin; dose, timing and release formulation vary.
Read the interaction guide →Concentrated oral L-tryptophan supplements, not routine food protein.
Read the interaction guide →Oral potassium supplements and potassium-containing salt substitutes during oral benazepril treatment. The concern is the potassium dose from all products, not a single brand or salt. This is not a blanket instruction to avoid potassium-containing foods.
Read the interaction guide →Oral quercetin supplements with caffeine; studied capsule doses do not establish effects of every food or formulation.
Read the interaction guide →Oral iron with caffeine; coffee, tea, meals and pure-caffeine tablets have different constituents.
Read the interaction guide →Oral B-complex products with caffeine; individual vitamin doses, coffee exposure and isolated caffeine are distinguished.
Read the interaction guide →Oral Panax ginseng and caffeine; red-root extracts, unspecified ginseng and other species are not interchangeable.
Read the interaction guide →Oral Citrus aurantium supplements with caffeine; ordinary food, topical oil and different synephrine compounds are not equivalent.
Read the interaction guide →Paullinia cupana seed preparations with oral caffeine; seed powder, extracts and multicomponent products vary.
Read the interaction guide →Oral Echinacea purpurea root preparation with caffeine; different species, aerial parts and mixed products require separate assessment.
Read the interaction guide →Oral zinc and caffeine; animal infusion experiments and tissue measurements do not directly establish human dosing advice.
Read the interaction guide →Ephedra sinica products containing ephedrine alkaloids with oral caffeine; purified ephedrine and botanical mixtures are explicitly distinguished.
Read the interaction guide →Abaloparatide 80 mcg/day by subcutaneous injection in osteoporosis care; not teriparatide or another parathyroid-hormone product.
Read the interaction guide →Abaloparatide 80 mcg/day by subcutaneous injection in osteoporosis care; not teriparatide or another parathyroid-hormone product.
Read the interaction guide →Abaloparatide 80 mcg/day by subcutaneous injection in osteoporosis care; not teriparatide or another parathyroid-hormone product.
Read the interaction guide →Oral delafloxacin meglumine tablets with oral iron preparations and iron-containing multivitamins. The interaction concerns absorption in the digestive tract, not every route or trace exposure.
Read the interaction guide →Oral copper supplements with delafloxacin meglumine tablets. Copper salt, amount and other ingredients remain part of the assessment; another fluoroquinolone is not a substitute.
Read the interaction guide →Oral delafloxacin meglumine tablets with magnesium-containing oral antacids and products. The interaction concerns absorption in the digestive tract, not every route or trace exposure.
Read the interaction guide →Oral delafloxacin meglumine tablets with aluminum-containing oral antacids. The interaction concerns absorption in the digestive tract, not every route or trace exposure.
Read the interaction guide →Oral delafloxacin meglumine tablets with oral zinc products and zinc-containing multivitamins. The interaction concerns absorption in the digestive tract, not every route or trace exposure.
Read the interaction guide →Oral calcium supplements with oral delafloxacin meglumine tablets. Intravenous calcium compatibility is discussed only to distinguish route; it is not evidence for an oral interaction.
Read the interaction guide →Oral bisoprolol with the exact supplement preparation described below. Calcium carbonate, mixed salts and calcium-containing food are not interchangeable exposures.
Read the interaction guide →Oral bisoprolol with the exact supplement preparation described below.
Read the interaction guide →Oral bisoprolol with the exact supplement preparation described below.
Read the interaction guide →Oral bisoprolol with the exact supplement preparation described below.
Read the interaction guide →Oral bisoprolol with the exact supplement preparation described below.
Read the interaction guide →Oral bisoprolol with the exact supplement preparation described below. Calcium carbonate, mixed salts and calcium-containing food are not interchangeable exposures.
Read the interaction guide →Oral bisoprolol with the exact supplement preparation described below.
Read the interaction guide →Oral bisoprolol with the exact supplement preparation described below.
Read the interaction guide →Chromium supplements, not an established deficiency diagnosis; oral versus injected semaglutide.
Read the interaction guide →Psyllium husk powder, commonly Plantago ovata; not interchangeable with Plantago afra whole seed or a mixed-fiber formula.
Read the interaction guide →Asian Panax ginseng root and defined extracts; not American ginseng or all processed products.
Read the interaction guide →Oral berberine products; semaglutide tablets versus weekly subcutaneous injections.
Read the interaction guide →Plantago afra seed covered by the EMA seed monograph; not automatically psyllium husk from Plantago ovata.
Read the interaction guide →Momordica charantia capsules versus food, juice, seeds and other extracts; semaglutide route matters.
Read the interaction guide →Defined fenugreek capsules versus seed foods, teas and extracts; oral semaglutide and weekly injections differ.
Read the interaction guide →Adult oral Biktarvy with iron supplements or iron-containing antacids. Direct evidence used ferrous fumarate 324 mg, approximately 107 mg elemental iron; the same measured effect is not assigned to every iron salt or dose.
Read the interaction guide →Adult oral Biktarvy with Hypericum perforatum, commonly called St. John’s wort. The fixed combination contains bictegravir, emtricitabine and tenofovir alafenamide; induction concerns are not treated as a measured effect on every component.
Read the interaction guide →Adult oral Biktarvy with magnesium-containing antacids or nutritional supplements. Direct evidence used magnesium hydroxide combined with aluminum hydroxide; magnesium glycinate, citrate and other stand-alone supplements were not separately tested.
Read the interaction guide →Adult oral Biktarvy with Echinacea purpurea products. Indirect studies used specified root or oral preparations; other echinacea species, plant parts, extracts and mixed cold remedies are not assumed equivalent.
Read the interaction guide →Adult oral bictegravir in Biktarvy and aluminum-containing antacids. Direct research used aluminum hydroxide combined with magnesium hydroxide; isolated aluminum products, dietary aluminum and other formulations were not separately tested.
Read the interaction guide →Adult oral Biktarvy and calcium-containing supplements or antacids. Direct pharmacokinetic research used calcium carbonate 1,200 mg, approximately 480 mg elemental calcium. Other calcium salts and multicomponent products were not separately measured.
Read the interaction guide →Adult oral Biktarvy and multivitamin products, especially those containing calcium, iron, magnesium, aluminum or zinc. Evidence is ingredient-specific; vitamin-only products and every commercial mixture were not directly tested.
Read the interaction guide →Oral carbinoxamine with the specific preparation described below. Only the solid oral potassium chloride and delayed-transit condition is supported; ordinary foods, other salts, liquids and intravenous replacement are distinct.
Read the interaction guide →Oral carbinoxamine with the specific preparation described below.
Read the interaction guide →Oral carbinoxamine with the specific preparation described below.
Read the interaction guide →Oral carbinoxamine with the specific preparation described below.
Read the interaction guide →Oral carbinoxamine with the specific preparation described below.
Read the interaction guide →Oral carbinoxamine with the specific preparation described below.
Read the interaction guide →Oral carbinoxamine with the specific preparation described below.
Read the interaction guide →Exact Valeriana officinalis species; root preparations, extracts and doses vary. Do not equate this with an unidentified valerian-root node.
Read the interaction guide →Hypericum perforatum oral supplements; extract composition differs.
Read the interaction guide →Generic root/rhizome identity; confirm Valeriana officinalis before applying species-specific guidance.
Read the interaction guide →Piper methysticum beverages and extracts; product strength varies.
Read the interaction guide →Cannabidiol is the exact pair node; the current claim also mentions Cannabis sativa. Purified CBD, THC-containing products, hemp foods and topical products require separate interpretation.
Read the interaction guide →Oral S-adenosylmethionine supplements; formulations and doses vary.
Read the interaction guide →Oral cefuroxime axetil and swallowed calcium carbonate with acid-neutralizing activity. A calcium carbonate supplement requires review of dose and preparation; no extension to other calcium salts or injected cefuroxime.
Read the interaction guide →Oral cefuroxime axetil with sodium bicarbonate used to neutralize stomach acid. Ordinary baking amounts, intravenous bicarbonate and injected cefuroxime are outside the assessed absorption mechanism.
Read the interaction guide →Oral cefuroxime axetil with acid-neutralizing magnesium products, especially magnesium hydroxide antacids. Other magnesium salts, laxative preparations, dietary magnesium and parenteral routes need separate assessment.
Read the interaction guide →Oral cefuroxime axetil and aluminum-containing antacids such as aluminum hydroxide. Elemental aluminum, ordinary environmental exposure and parenteral cefuroxime are outside the absorption precaution.
Read the interaction guide →Oral cefuroxime axetil tablets with oral aluminum hydroxide antacid preparations. No transfer to injected cefuroxime sodium or unrelated aluminum compounds.
Read the interaction guide →Oral cefuroxime axetil with calcium products that act as antacids, particularly calcium carbonate. Dietary calcium, milk, other calcium salts and injected products are not automatically equivalent.
Read the interaction guide →Oral cefuroxime axetil and oral magnesium hydroxide products with acid-neutralizing activity, including combination antacids. Milk of magnesia used as a laxative may require its own dose and schedule review.
Read the interaction guide →Cefuroxime exposure and oral or feeding-tube Lactobacillus preparations. Available studies include mixed antibiotics, specific strains and sometimes other organisms; they do not isolate a universal cefuroxime timing effect.
Read the interaction guide →Applies to amphetamine aspartate with St. John's wort products; the risk concerns overlapping effects on serotonin. Evidence includes a mixed-salt product containing this ingredient, with the finding limited to its documented active-ingredient mechanism.
Read the interaction guide →Applies to oral amphetamine aspartate and antacids that meaningfully reduce acidity; other heartburn medicines and mineral preparations are not interchangeable. Evidence includes a mixed-salt product containing this ingredient, without transferring effects from its other components.
Read the interaction guide →Applies to dextroamphetamine saccharate with St. John's wort products; the risk concerns overlapping effects on serotonin. Evidence includes a mixed-salt product containing this ingredient, with the finding limited to its documented active-ingredient mechanism.
Read the interaction guide →Applies to oral dextroamphetamine saccharate and antacids that meaningfully reduce acidity; other heartburn medicines and mineral preparations are not interchangeable. Evidence includes a mixed-salt product containing this ingredient, without transferring effects from its other components.
Read the interaction guide →Oral cephalexin capsules with immediate-release zinc sulfate. The trial used 56 mg elemental zinc; other salts, lower doses and repeated regimens are not equally studied.
Read the interaction guide →Oral cephalexin and live Lactobacillus-containing probiotics. The broad genus is not a single strain or product, and the evidence depends on the exact preparation.
Read the interaction guide →Oral Valeriana officinalis root preparations; other species, extracts and mixed products remain distinct.
Read the interaction guide →Oral Hypericum perforatum products; case-series extracts and doses were not characterized.
Read the interaction guide →Radix et Rhizoma Valerianae has unresolved species identity; Valeriana officinalis evidence applies only after a match is confirmed.
Read the interaction guide →Oral L-5-hydroxytryptophan; not L-tryptophan, another isomer or whole Griffonia seed.
Read the interaction guide →Ginkgo biloba leaf medicinal preparations; seed-toxin reports do not establish the effect of every leaf extract.
Read the interaction guide →Oral melatonin; prolonged-release product guidance is distinct from immediate-release supplements.
Read the interaction guide →Oral L-tryptophan supplements; normal protein-containing foods and L-5-HTP are different exposures.
Read the interaction guide →Oral Hypericum perforatum extracts; hyperforin content and the exact medication metabolism matter.
Read the interaction guide →Radix et Rhizoma Valerianae has unresolved species identity; Valeriana officinalis evidence applies only after a match is confirmed.
Read the interaction guide →Oral Withania somnifera preparations; the cited sleep trial used a specific root extract, not arbitrary leaf or mixed products.
Read the interaction guide →Oral Piper methysticum; extract, dose and other sedatives must be identified.
Read the interaction guide →Oral Passiflora incarnata aerial-part preparations; other species and extracts are not equivalent.
Read the interaction guide →Oral melatonin; prolonged-release product guidance is distinct from immediate-release supplements.
Read the interaction guide →Oral Matricaria chamomilla, also called German chamomile or Matricaria recutita; not Roman chamomile or every plant part.
Read the interaction guide →Arctostaphylos uva-ursi species entry; regulatory evidence concerns specified oral leaf preparations.
Read the interaction guide →Glycyrrhiza glabra, particularly glycyrrhizin-containing root preparations; deglycyrrhizinated products are not equivalent.
Read the interaction guide →Aloe vera: oral latex or latex-containing whole leaf is distinct from inner-leaf gel and topical gel.
Read the interaction guide →Oral chlorothiazide with supplemental calcium; salt and elemental calcium amount matter, and food intake is not identical to concentrated supplements.
Read the interaction guide →Herba Taraxaci herb-material entry; confirm species and parts. Fresh leaf extract and root-with-herb are not automatically the same product.
Read the interaction guide →Equisetum arvense aerial dry extract evidence; other horsetail species and blends are distinct.
Read the interaction guide →Juniperus communis species entry; regulatory evidence mainly concerns cone berries and defined oral extracts, not all oils or plant parts.
Read the interaction guide →Oral chlorothiazide with supplemental vitamin D2 or D3; active calcitriol and topical analogs are different exposures.
Read the interaction guide →Generic licorice root/rhizome entry. Confirm Glycyrrhiza species and glycyrrhizin content; EMA guidance covers roots of G. glabra, G. inflata and G. uralensis.
Read the interaction guide →Oral chlorpromazine with the exact supplement preparation described.
Read the interaction guide →Oral chlorpromazine with the exact supplement preparation described.
Read the interaction guide →Oral chlorpromazine with the exact supplement preparation described.
Read the interaction guide →Oral chlorpromazine with the exact supplement preparation described.
Read the interaction guide →Oral chlorpromazine with the exact supplement preparation described.
Read the interaction guide →Oral chlorpromazine with the exact supplement preparation described.
Read the interaction guide →Oral chlorpromazine with the exact supplement preparation described.
Read the interaction guide →Arctostaphylos uva-ursi species entry; regulatory evidence concerns specified oral leaf preparations.
Read the interaction guide →Glycyrrhiza glabra, particularly glycyrrhizin-containing root preparations; deglycyrrhizinated products are not equivalent.
Read the interaction guide →Oral chlorthalidone with supplemental calcium; salt and elemental calcium amount matter, and food intake is not identical to concentrated supplements.
Read the interaction guide →Herba Taraxaci herb-material entry; confirm species and parts. Fresh leaf extract and root-with-herb are not automatically the same product.
Read the interaction guide →Equisetum arvense aerial dry extract evidence; other horsetail species and blends are distinct.
Read the interaction guide →Juniperus communis species entry; regulatory evidence mainly concerns cone berries and defined oral extracts, not all oils or plant parts.
Read the interaction guide →Oral chlorthalidone with supplemental vitamin D2 or D3; active calcitriol and topical analogs are different exposures.
Read the interaction guide →Generic licorice root/rhizome entry. Confirm Glycyrrhiza species and glycyrrhizin content; EMA guidance covers roots of G. glabra, G. inflata and G. uralensis.
Read the interaction guide →Oral willow bark products with oral immediate-release etodolac capsules or tablets. Medicinal Salix bark guidance has defined preparation scope; exact species and salicin content must be checked.
Read the interaction guide →Oral garlic supplements with oral immediate-release etodolac capsules or tablets. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable.
Read the interaction guide →Oral iron tablets with oral immediate-release etodolac capsules or tablets. Dietary iron, liquid formulations and intravenous iron are distinct exposures.
Read the interaction guide →Oral ginger root powder with oral immediate-release etodolac capsules or tablets. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable.
Read the interaction guide →Oral Ginkgo biloba with oral immediate-release etodolac capsules or tablets. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable.
Read the interaction guide →Oral potassium replacement with oral immediate-release etodolac capsules or tablets. Potassium chloride solution evidence supplies a regulatory class bridge; dietary potassium and other routes are separate.
Read the interaction guide →Oral cefdinir capsules and oral iron supplements. Infant formula with cefdinir suspension is considered separately; its findings do not clear therapeutic iron doses.
Read the interaction guide →Oral cefdinir capsules with magnesium-containing antacids. Combined Maalox TC is the directly studied exposure; unrelated routes and untested nutritional forms are not assumed equivalent.
Read the interaction guide →Oral cefdinir capsules with aluminum-containing antacids. Combined Maalox TC is the directly studied exposure; unrelated routes and untested nutritional forms are not assumed equivalent.
Read the interaction guide →Trivalent oral chromium supplements; picolinate trial evidence does not represent every salt or industrial hexavalent chromium.
Read the interaction guide →Asian Panax ginseng, including specific root-extract studies; American ginseng is a separate species.
Read the interaction guide →Oral aloe gel or whole-leaf products versus injected human regular insulin. Topical gel, laxative latex and experimental oral-insulin formulations are different exposures.
Read the interaction guide →Dried Zingiber officinale rhizome powder, often sold as root powder; not all extracts, oils or isolated gingerols.
Read the interaction guide →Opuntia ficus-indica exact species; steamed nopal, dried capsules, fruit and extracts are different exposures.
Read the interaction guide →Momordica charantia oral capsule evidence; food, juice, seed and concentrated extracts differ.
Read the interaction guide →Oral niacin, especially pharmacologic nicotinic acid; dietary vitamin B3 and nicotinamide are different exposures.
Read the interaction guide →Oral ciprofloxacin tablets and oral iron preparations. Intravenous iron and injected ciprofloxacin are not assessed by these gut-absorption studies.
Read the interaction guide →Oral ciprofloxacin with magnesium-containing oral products; direct clinical study evidence concerns combined magnesium/aluminum antacids. This is not an assessment of low blood magnesium or injected magnesium.
Read the interaction guide →Oral ciprofloxacin tablets with aluminum hydroxide or aluminum/magnesium antacids. Dietary traces, topical products, injections and unrelated aluminum compounds are outside this assessment.
Read the interaction guide →Oral ciprofloxacin tablets with oral zinc-containing preparations. Available human combination-product findings are not zinc-only effect estimates.
Read the interaction guide →Oral ciprofloxacin tablets with calcium-containing products. Direct trial evidence is strongest for calcium carbonate; meal-related instructions are a separate part of the label.
Read the interaction guide →Oral ciprofloxacin with multivitamins or prenatal products that contain interacting minerals. A vitamin-only product is not automatically covered by the mineral interaction.
Read the interaction guide →Oral Hypericum perforatum with citalopram hydrobromide tablets.
Read the interaction guide →Oral curcumin; not automatically equivalent to turmeric food or every enhanced-absorption formulation.
Read the interaction guide →Oral Crocus sativus versus isolated crocin; preparations and comparison designs distinguished.
Read the interaction guide →Combined B12, folic acid and B6 intervention; not isolated B12 or routine dietary intake.
Read the interaction guide →Oral melatonin; one 3 mg product in a polypharmacy case, not every formulation.
Read the interaction guide →Oral S-adenosylmethionine supplement; concentrated supplement distinct from ordinary dietary nutrients.
Read the interaction guide →Oral willow bark products with oral mefenamic acid 250 mg capsules. Medicinal Salix bark guidance has defined preparation scope; exact species and salicin content must be checked.
Read the interaction guide →Oral garlic supplements with oral mefenamic acid 250 mg capsules. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable.
Read the interaction guide →Oral iron tablets with oral mefenamic acid 250 mg capsules. Dietary iron, liquid formulations and intravenous iron are distinct exposures.
Read the interaction guide →Oral Ginkgo biloba with oral mefenamic acid 250 mg capsules. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable.
Read the interaction guide →Oral purified methylsulfonylmethane (MSM) with oral mefenamic acid capsules, explicitly bridged to mefenamate IN.
Read the interaction guide →Oral magnesium hydroxide antacid immediately following oral mefenamic acid, bridged to exact mefenamate IN. Other magnesium salts, foods and routes are not equivalent.
Read the interaction guide →Oral Allium sativum products with oral glimepiride; food, extracts and garlic-plus-oil mixtures are not interchangeable.
Read the interaction guide →Asian ginseng, Panax ginseng, with oral glimepiride; root and berry extracts differ, and American ginseng is a separate species.
Read the interaction guide →Oral inner-leaf Aloe vera gel with glimepiride. Latex, whole-leaf products and topical use are outside the gel study findings.
Read the interaction guide →Zingiber officinale powder, commonly labeled ginger root, with oral glimepiride. Culinary amounts, extracts and oils are different exposures.
Read the interaction guide →Oral charcoal products; the evidence concerns laboratory-tested activated charcoal, not every powder or consumer product.
Read the interaction guide →Momordica charantia fruit preparations with oral glimepiride. Prediabetes studies without medicines and specified extracts are not equivalent to all seed, juice or food products.
Read the interaction guide →Trigonella foenum-graecum seed preparations with oral glimepiride; medicinal amounts, culinary use and mixed products must be distinguished.
Read the interaction guide →Konjac glucomannan supplements with oral glimepiride; the tested laboratory preparation does not establish effects of every food or fiber blend.
Read the interaction guide →Guar gum supplements with oral glimepiride. Studies of diet-treated diabetes or a different sulfonylurea remain indirect.
Read the interaction guide →Pharmacologic oral nicotinic acid with glimepiride; ordinary dietary niacin, nicotinamide and other vitamin B3 products are not automatically equivalent.
Read the interaction guide →Oral Hypericum perforatum products; case-series extracts and doses were not characterized.
Read the interaction guide →Radix et Rhizoma Valerianae has unresolved species identity; Valeriana officinalis evidence applies only after a match is confirmed.
Read the interaction guide →Oral Piper methysticum; extract, dose and other sedatives must be identified.
Read the interaction guide →Oral Passiflora incarnata aerial-part preparations; other species and extracts are not equivalent.
Read the interaction guide →Oral clonazepam and melatonin; direct observational studies concern isolated REM sleep behavior disorder, including sustained-release melatonin, not routine seizure or panic treatment.
Read the interaction guide →Oral Matricaria chamomilla, also called German chamomile or Matricaria recutita; not Roman chamomile or every plant part.
Read the interaction guide →Oral coenzyme Q10 with oral clonidine; study products and treatment durations vary.
Read the interaction guide →Oral Allium sativum preparations with oral clonidine. Evidence for aged extract does not automatically apply to raw garlic, garlic oil or every supplement.
Read the interaction guide →Oral Hypericum perforatum with oral clonidine. Results from other Hypericum species or isolated constituents are not assigned to this product.
Read the interaction guide →Oral Panax ginseng with oral clonidine. Defined root extracts, red ginseng and isolated saponins are separate exposures; other ginseng species are not interchangeable.
Read the interaction guide →Oral Valeriana officinalis root or rhizome products with oral clonidine. Multi-herb sleep blends and other valerian species require separate assessment.
Read the interaction guide →Oral Plantago afra seed or seed powder with oral clonidine. This is not an automatic substitution of Plantago ovata husk or a different fiber preparation.
Read the interaction guide →Oral purified yohimbine with oral immediate-release clonidine, both studied as hydrochloride salts. Acute volunteer results do not define a safe dose for chronic treatment.
Read the interaction guide →Oral Pausinystalia johimbe/yohimbe bark preparations with oral clonidine. The trial used isolated yohimbine hydrochloride; botanical content is an explicit uncertainty.
Read the interaction guide →Oral Plectranthus barbatus root preparations with oral clonidine. Historical medicinal studies use Coleus/forskohlii naming; naming and extract identity require confirmation, and isolated forskolin is a separate exposure.
Read the interaction guide →Oral hawthorn fruit (Fructus Crataegi) with oral clonidine. The inspected controlled trial used Crataegus pinnatifida var. major fruit; other species and plant parts remain distinct.
Read the interaction guide →Oral nutritional chromium supplements with subcutaneous tirzepatide; the inspected trial used chromium picolinate, not every chromium salt or industrial chromium exposure.
Read the interaction guide →Oral Panax ginseng root preparations with subcutaneous tirzepatide. Korean red root extract, vinegar extract and isolated ginsenoside Re are distinct exposures; other Panax species are not substituted.
Read the interaction guide →Oral Camellia sinensis leaf extract with subcutaneous tirzepatide; caffeine-containing preparations distinguished from low-caffeine or caffeine-free products and from catechin content.
Read the interaction guide →Oral berberine supplements with subcutaneous tirzepatide. The original trial used berberine hydrochloride; mixed botanical products and other salts are not established equivalents.
Read the interaction guide →Vitamin B12 nutrition and separately taken oral supplements during subcutaneous tirzepatide therapy. Compounded products mixing tirzepatide and B12 in the same injection are a distinct formulation exposure; they are not equivalent to a B12 tablet or a separate prescribed injection.
Read the interaction guide →Oral caffeine from supplements and beverages with subcutaneous tirzepatide; total intake and individual sensitivity matter.
Read the interaction guide →Oral Senna alexandrina laxatives with subcutaneous tirzepatide. The inspected EMA monograph covers pods; leaf and combination products require separate formulation review.
Read the interaction guide →Oral Momordica charantia products with subcutaneous tirzepatide. Direct botanical trial evidence is limited to dried unripe fruit pulp with seeds removed; food, juice, seed and extract products differ.
Read the interaction guide →Oral Gymnema sylvestre products with subcutaneous tirzepatide. Evidence concerns GS4 leaf extract, not every plant part, preparation or unrelated plant sold under a similar common name.
Read the interaction guide →Oral Frangula purshiana bark laxatives, called Rhamnus purshiana in the EMA monograph, with subcutaneous tirzepatide. Other Frangula species are not equivalent.
Read the interaction guide →Oral Trigonella foenum-graecum products with subcutaneous tirzepatide. The inspected trial used a specified hydroalcoholic seed extract, not food seasoning, whole seeds or every extract.
Read the interaction guide →Oral Larrea tridentata (chaparral) products with oral adagrasib. Product composition and dose in historical spontaneous reports are incompletely characterized.
Read the interaction guide →Oral Rheum undulatum products with oral adagrasib. Do not substitute evidence for R. palmatum, R. officinale, their hybrids or unidentified medicinal rhubarb.
Read the interaction guide →Oral Hypericum perforatum products with oral adagrasib. Hyperforin content and repeated use affect enzyme induction; low-hyperforin products and teas are not assumed safe substitutes.
Read the interaction guide →Oral Camellia sinensis leaf extracts during oral adagrasib treatment. Concentrated extracts and their EGCG content are distinct from brewed tea, caffeine content and total leaf weight.
Read the interaction guide →Symphytum officinale oral products with oral adagrasib, distinguished from short-term skin use of specified low-pyrrolizidine-alkaloid root medicines. Historical common-name comfrey leaf cases do not establish exact species identity.
Read the interaction guide →Adequate magnesium intake and clinician-directed replacement during oral adagrasib therapy. Dietary intake, oral supplements and treatment of clinically significant electrolyte abnormalities are distinct decisions.
Read the interaction guide →Oral Hydrastis canadensis root products with oral adagrasib. Authenticated root extract in the clinical probe study is not equivalent to isolated berberine or every goldenseal product.
Read the interaction guide →Oral Senna alexandrina stimulant laxatives with oral adagrasib. The inspected monograph covers defined pod preparations; chronic misuse, bowel cleansing, leaf products and combinations are distinct exposures.
Read the interaction guide →Adequate potassium intake and clinician-directed replacement during oral adagrasib therapy. Dietary intake, oral supplements and treatment of clinically significant electrolyte abnormalities are distinct decisions.
Read the interaction guide →Oral Glycyrrhiza glabra root products containing glycyrrhizin. This assessment does not treat deglycyrrhizinated licorice, topical preparations, other Glycyrrhiza species or licorice-flavored products as equivalent.
Read the interaction guide →Scutellaria lateriflora (American skullcap) oral preparations, specifically characterized aerial-part extracts where stated. Scutellaria baicalensis and isolated flavonoids are distinct.
Read the interaction guide →Valeriana officinalis root and rhizome preparations taken by mouth; blends and other valerian species are not equivalent.
Read the interaction guide →Oral chaparral products identified as Larrea tridentata. Evidence does not establish equivalent risks for other Larrea species, purified constituents or topical preparations.
Read the interaction guide →Orally ingested Hyoscyamus niger containing pharmacologically active antimuscarinic alkaloids; unknown-strength and highly diluted preparations require separate assessment.
Read the interaction guide →Applies to Hypericum perforatum, commonly called St. John's wort. Product strength varies, and the evidence does not define a safe preparation, dose, or washout interval.
Read the interaction guide →Oral Withania somnifera preparations; Sensoril trial findings cannot be extended to every root, leaf or mixed product.
Read the interaction guide →Oral Camellia Sinensis Leaf Extract that contains caffeine. Catechin or extract mass alone does not establish caffeine exposure. Coffea arabica seed extract is a separate botanical and is not assessed in this pair.
Read the interaction guide →Piper methysticum oral extracts and beverages; preparation, plant material and co-exposures vary.
Read the interaction guide →Oral Citrus aurantium supplements, with attention to extract composition, synephrine content and additional ingredients. Whole plant, isolated p-synephrine, juice and multi-ingredient products are not assumed interchangeable.
Read the interaction guide →Orally ingested Atropa belladonna containing pharmacologically active antimuscarinic alkaloids; unknown-strength and highly diluted preparations require separate assessment.
Read the interaction guide →Humulus lupulus hop-strobile preparations taken by mouth; beer, isolated constituents and valerian-hops blends are not interchangeable.
Read the interaction guide →Oral caffeine-containing Paullinia cupana seed preparations, including the var. sorbilis material in the final EMA assessment. Whole plant, other parts and caffeine-free formulations are not assigned seed-equivalent exposure.
Read the interaction guide →Caffeine from drinks, foods and supplements during oral clozapine treatment. The studies used different caffeine amounts and do not establish a daily limit that is safe for everyone.
Read the interaction guide →Oral Matricaria chamomilla (German chamomile) flower extract. Evidence from flowering-top extract is preparation-specific; Roman chamomile, tea and topical use are not equivalent.
Read the interaction guide →Oral caffeine-containing Cola acuminata seed preparations. Other Cola species, Garcinia kola, other plant parts and cola beverages cannot be assumed equivalent.
Read the interaction guide →Passiflora incarnata above-ground herb preparations; other Passiflora species, fruit products and multi-herb blends are separate exposures.
Read the interaction guide →Oral senna leaf/fruit laxative preparations or standardized sennosides; not all extracts are dose-equivalent.
Read the interaction guide →Medicinal oral whole or powdered Plantago afra seed used as a bulk-forming laxative. Other plant parts, extracts, food fibre and Plantago ovata husk are not treated as interchangeable.
Read the interaction guide →Products labeled charcoal or charcoal powder, without a specified activation process. The evidence concerns medical activated charcoal, mainly in poisoning care, and does not establish equivalent effects for every oral charcoal supplement.
Read the interaction guide →Oral melatonin with oral clozapine. The clearest official melatonin information concerns a 2 mg prolonged-release medicine; effects cannot be assumed identical across doses and formulations.
Read the interaction guide →Oral S-adenosylmethionine supplements; not methionine, endogenous SAM metabolism or injected formulations.
Read the interaction guide →Melissa officinalis oral extract; the acute study used a standardized product. Tea, essential oils, other species and blends are not assumed equivalent.
Read the interaction guide →Oral laxative-active Frangula purshiana bark preparations, including standardized cascara bark tea or extracts.
Read the interaction guide →The direct report concerns inhaled smoke from cannabis together with tobacco. Oral extracts, purified CBD, hemp seed products and noncombustion routes are not equivalent exposures.
Read the interaction guide →Oral caffeine-containing Ilex paraguariensis leaf preparations. Other Ilex species, non-leaf material and decaffeinated products are distinct. Roasted leaf is not equated with the non-roasted preparation covered by the HMPC monograph.
Read the interaction guide →Oral Mitragyna speciosa products. A single low-dose leaf tea study does not represent concentrated alkaloid products or prolonged use.
Read the interaction guide →Matricaria chamomilla species-level entry; oral tea, flowering-top extracts and other preparations are not interchangeable. Roman chamomile is a different botanical.
Read the interaction guide →Generic root/rhizome node; confirm Valeriana officinalis before applying its guidance.
Read the interaction guide →Piper methysticum beverages and extracts; not isolated kavalactones or every product.
Read the interaction guide →Oral L-5-HTP supplements, not ordinary dietary tryptophan.
Read the interaction guide →Hydrastis canadensis extract products; not isolated berberine or every root preparation.
Read the interaction guide →Oral melatonin products; dose and release form vary.
Read the interaction guide →Juglans nigra nut, leaf, hull and extract products must be distinguished; Juglans regia is a different species.
Read the interaction guide →Camellia sinensis brewed green/black tea versus concentrated extract; preparation and amount differ.
Read the interaction guide →Asian Panax ginseng root and specific extracts; American ginseng is a different species. Exact insulin glargine single-insulin product scope.
Read the interaction guide →Oral Aloe vera gel versus laxative latex, whole leaf and topical products. Glargine U100/U300 product differences retained.
Read the interaction guide →Dried Zingiber officinale rhizome powder, sold as root powder; oils and concentrated extracts differ. Exact insulin glargine scope.
Read the interaction guide →Oral Coenzyme Q10 products during prescribed oral lofexidine treatment; no assumed equivalence of every formulation.
Read the interaction guide →Inventory root/rhizome name has unresolved species identity. Valeriana officinalis sources apply conditionally only after that species is confirmed; other Valeriana species are not assumed equivalent.
Read the interaction guide →Oral Piper methysticum products; extract composition and preparation vary.
Read the interaction guide →Oral L-5-hydroxytryptophan, not L-tryptophan or an assumed equivalent whole-seed extract.
Read the interaction guide →Measured magnesium status and clinician-directed correction during oral lofexidine treatment; no universal supplement form, dose or route.
Read the interaction guide →Crataegus monogyna with plant part and preparation specified; fruit-extract findings are not automatically leaf, flower, berry-mixture or other-species findings.
Read the interaction guide →Plantago afra ripe whole dry seed or powdered seed; not an assumed equivalent Plantago ovata husk or other fiber.
Read the interaction guide →Oral melatonin; the inspected Circadin information concerns a licensed prolonged-release preparation and does not define every supplement.
Read the interaction guide →Measured potassium status and clinician-directed correction during oral lofexidine treatment; no universal supplement form, dose or route.
Read the interaction guide →Oral L-arginine supplements. Intravenous high-dose findings are not treated as equivalent to oral use.
Read the interaction guide →Oral Crataegus monogyna products with oral lisinopril. Species, plant part, extraction method and strength need to be identified. Evidence for other hawthorn species, mixed extracts or root products is not automatically applicable.
Read the interaction guide →Applies to systemic lisinopril with concentrated potassium products; ordinary food intake is not automatically equivalent.
Read the interaction guide →Most relevant to starting or increasing systemic lisinopril in people with salt or fluid depletion or concurrent diuretic use.
Read the interaction guide →Asian Panax ginseng and specific extracts; American ginseng is a separate species.
Read the interaction guide →Oral Aloe vera inner-leaf gel; latex, whole leaf and topical products differ.
Read the interaction guide →Plantago afra seeds, also covered with P.indica in the monograph; not automatically P.ovata husk, extracts or every botanical formulation.
Read the interaction guide →Oral intestinal adsorbent charcoal, generally activated preparations; ordinary nonadsorbent carbon is not assumed equivalent.
Read the interaction guide →Oral Momordica charantia capsules; food, juice, seed and extracts differ.
Read the interaction guide →Oral pancreatin preparations with carbohydrate-splitting enzymes such as amylase; enzyme composition matters.
Read the interaction guide →Oral konjac glucomannan; dose, viscosity and preparation differ. Miglitol tablets act locally in the intestine.
Read the interaction guide →Oral guar gum fiber; study doses and viscosity do not represent every modified guar product.
Read the interaction guide →Edible grapefruit flesh from Citrus paradisi with oral systemic cyclosporine. Whole-fruit avoidance comes from the exact medicine’s label; juice trial results provide supporting context and are not described as flesh experiments.
Read the interaction guide →Oral quercetin supplements with systemic oral cyclosporine. This assessment does not assign the same effect to ordinary dietary amounts, rutin, quercetin glycosides or enhanced-bioavailability formulations. Animal cyclosporine preparations are identified separately.
Read the interaction guide →Oral potassium chloride supplements, replacement products and potassium-chloride salt substitutes with systemic oral cyclosporine. Potassium from this salt is the relevant exposure. Concentrated intravenous potassium is outside this article’s administration advice.
Read the interaction guide →Applies to systemic cyclosporine, with much of the direct evidence from oral treatment in transplant recipients; it does not apply to cyclosporine eye drops.
Read the interaction guide →Oral tocophersolan, d-alpha-tocopheryl polyethylene glycol 1000 succinate or TPGS, with systemic oral cyclosporine. Historical Liqui-E and current Vedrop are identified separately. Ordinary tocopherol, tocopheryl acetate, topical vitamin E and unspecified excipient amounts are not assigned the same effect.
Read the interaction guide →Oral berberine with systemic oral cyclosporine. The human reports do not fully resolve the cyclosporine formulation or berberine salt, so their results are not interchangeable with every extract or product containing berberine.
Read the interaction guide →Cannabidiol used with systemic cyclosporine, with oral products the practical focus. CBD composition and dose need confirmation. Findings are not automatically applicable to topical products, THC-containing mixtures or another transplant medicine.
Read the interaction guide →Applies to oral or intravenous cyclosporine, not eye drops; replacement and monitoring depend on the treatment setting.
Read the interaction guide →Scutellaria baicalensis, Chinese skullcap, especially oral root decoctions, with systemic oral cyclosporine. Isolated baicalin, baicalein, other skullcap species and multi-herb formulas are different preparations and are not treated as direct substitutes for the root.
Read the interaction guide →Applies to oral or intravenous systemic cyclosporine, not eye drops; potassium content and other potassium-raising medicines matter.
Read the interaction guide →Citrus paradisi, grapefruit, with oral cyclosporine. The original clinical studies tested juice; the cyclosporine label also names whole grapefruit. Seed extracts, peel extracts, pomelo and other citrus are distinct exposures and are not assigned the juice studies’ percentages.
Read the interaction guide →Oral Matricaria chamomilla, also called Matricaria recutita, with systemic oral cyclosporine. The clinical signal concerns tea; exact species authentication and product strength were incomplete. Roman chamomile, topical products and concentrated extracts are not interchangeable exposures.
Read the interaction guide →Oral willow bark products with oral nabumetone tablets. Medicinal Salix bark guidance has defined preparation scope; exact species and salicin content must be checked.
Read the interaction guide →Oral vitamin E supplements with oral nabumetone tablets. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable.
Read the interaction guide →Oral garlic supplements with oral nabumetone tablets. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable.
Read the interaction guide →Oral ginger root powder with oral nabumetone tablets. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable.
Read the interaction guide →Oral fish oil with oral nabumetone tablets. EPA/DHA fish oil, purified EPA, ALA and foods are distinct; nabumetone is a prodrug converted to 6MNA.
Read the interaction guide →Oral Ginkgo biloba with oral nabumetone tablets. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable.
Read the interaction guide →Oral potassium replacement with oral nabumetone tablets. Potassium chloride solution evidence supplies a regulatory class bridge; dietary potassium and other routes are separate.
Read the interaction guide →Oral omega-3 fatty acids with oral nabumetone tablets. EPA/DHA fish oil, purified EPA, ALA and foods are distinct; nabumetone is a prodrug converted to 6MNA.
Read the interaction guide →Oral Allium sativum preparations; food, oils, powders, aged extracts and blends differ. Medication scope is Humalog Mix75/25 or Mix50/50.
Read the interaction guide →Asian Panax ginseng root and extracts, not all ginseng species. Fixed Humalog mixture scope.
Read the interaction guide →Dried Zingiber officinale rhizome powder, marketed as root powder; extracts and oils differ. Whole Humalog premix scope.
Read the interaction guide →Gymnema sylvestre leaf extract GS4; other preparations differ. Humalog premixes contain both protamine and soluble lispro.
Read the interaction guide →Authenticated Trigonella foenum-graecum seeds in traditional preparations; ordinary seasoning differs. Humalog75/25 and50/50 contain fixed lispro components.
Read the interaction guide →Oral niacin, especially high-dose nicotinic acid; ordinary dietary vitamin B3 and nicotinamide differ. Whole Humalog Mix75/25 or Mix50/50 product scope.
Read the interaction guide →Oral Hypericum perforatum; different extracts and hyperforin content do not establish a universally safe product.
Read the interaction guide →Radix et Rhizoma Valerianae species unresolved; Valeriana officinalis and Valeriana glechomifolia are not interchangeable.
Read the interaction guide →Oral Piper methysticum extract, with product and co-sedative details retained.
Read the interaction guide →Oral L-5-hydroxytryptophan supplements, not L-tryptophan or ordinary protein foods.
Read the interaction guide →Oral Hydrastis canadensis extract; purified berberine and other species are not substitutes for the tested extract.
Read the interaction guide →Oral melatonin supplements; endogenous secretion and prolonged-release imipramine co-use studies are different evidence.
Read the interaction guide →Concentrated L-tryptophan supplements; ordinary dietary protein is not the studied exposure. IV challenge studies are separate from oral supplementation.
Read the interaction guide →Camellia sinensis, including black tea; brewed tea, isolated tannins, caffeine and concentrated extracts are distinct.
Read the interaction guide →Oral Curcuma longa with oral oxaprozin 600 mg tablets. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable.
Read the interaction guide →Oral willow bark products with oral oxaprozin 600 mg tablets. Medicinal Salix bark guidance has defined preparation scope; exact species and salicin content must be checked.
Read the interaction guide →Oral garlic supplements with oral oxaprozin 600 mg tablets. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable.
Read the interaction guide →Oral Panax ginseng with oral oxaprozin 600 mg tablets. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable.
Read the interaction guide →Oral ginger root powder with oral oxaprozin 600 mg tablets. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable.
Read the interaction guide →Oral Ginkgo biloba with oral oxaprozin 600 mg tablets. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable.
Read the interaction guide →Oral potassium replacement with oral oxaprozin 600 mg tablets. Potassium chloride solution evidence supplies a regulatory class bridge; dietary potassium and other routes are separate.
Read the interaction guide →Oral dexamethasone with grapefruit flesh. Available direct experimental interaction evidence used juice in rats, not flesh in humans.
Read the interaction guide →Oral dexamethasone and Glycyrrhiza glabra products. Defined glycyrrhizin and medicinal glycyrrhizinate studies are distinguished from botanical preparations.
Read the interaction guide →Oral dexamethasone with Hypericum perforatum preparations containing enzyme-inducing constituents. Hyperforin exposure varies across products.
Read the interaction guide →Adequate calcium intake during oral dexamethasone treatment, especially prolonged systemic glucocorticoid exposure. Nutritional adequacy is not automatic need for a supplement or evidence of impaired tablet absorption.
Read the interaction guide →Potassium intake and replacement during oral dexamethasone treatment. Monitoring and replacement depend on dose, indication, kidney function, other medicines and test results.
Read the interaction guide →Adequate vitamin D intake during oral dexamethasone treatment, especially prolonged systemic glucocorticoid exposure. Nutritional adequacy is not automatic need for a supplement or evidence of impaired tablet absorption.
Read the interaction guide →Applies to dextroamphetamine sulfate with St. John's wort products; the risk concerns overlapping effects on serotonin.
Read the interaction guide →Applies to oral dextroamphetamine sulfate and antacids that meaningfully reduce acidity; other heartburn medicines and mineral preparations are not interchangeable.
Read the interaction guide →Applies to dextroamphetamine with St. John's wort products; the risk concerns overlapping effects on serotonin.
Read the interaction guide →Applies to oral dextroamphetamine and antacids that meaningfully reduce acidity; other heartburn medicines and mineral preparations are not interchangeable.
Read the interaction guide →Hypericum perforatum oral supplements; extract constituents and strength vary.
Read the interaction guide →Generic root/rhizome node; identify the species before applying Valeriana officinalis evidence.
Read the interaction guide →Piper methysticum beverages and extracts; strength and co-ingredients vary.
Read the interaction guide →Citrus aurantium juice, fruit extracts and mixed supplements; not grapefruit or purified synephrine as interchangeable exposures.
Read the interaction guide →Oral L-5-hydroxytryptophan supplements, not ordinary food protein.
Read the interaction guide →Hydrastis canadensis root extracts; not isolated berberine or every commercial preparation.
Read the interaction guide →Oral melatonin products; dose and release form vary.
Read the interaction guide →Oral dicyclomine with the specific preparation described below.
Read the interaction guide →Oral dicyclomine with the specific preparation described below.
Read the interaction guide →Oral dicyclomine with the specific preparation described below.
Read the interaction guide →Oral dicyclomine with the specific preparation described below.
Read the interaction guide →Oral dicyclomine with the specific preparation described below.
Read the interaction guide →Oral dicyclomine with the specific preparation described below.
Read the interaction guide →Oral dicyclomine with the specific preparation described below. Only the solid oral potassium chloride and delayed-transit condition is supported; ordinary foods, other salts, liquids and intravenous replacement are distinct.
Read the interaction guide →Oral Curcuma longa products with prescription oral diflunisal. Exact preparation, dose and duration matter; other drugs and food exposures are not interchangeable.
Read the interaction guide →Oral medicinal willow bark preparations with prescription oral diflunisal. Salix species, salicin content and combination ingredients may vary.
Read the interaction guide →Oral calcium carbonate supplements or antacids with prescription oral diflunisal. Distinguish exact salt, antacid formulation and regular versus occasional use.
Read the interaction guide →Oral vitamin E supplements products with prescription oral diflunisal. Exact preparation, dose and duration matter; other drugs and food exposures are not interchangeable.
Read the interaction guide →Oral garlic supplements products with prescription oral diflunisal. Exact preparation, dose and duration matter; other drugs and food exposures are not interchangeable.
Read the interaction guide →Oral Hypericum perforatum products with prescription oral diflunisal. Herb interactions with other medicines do not establish a diflunisal interaction.
Read the interaction guide →Oral Panax ginseng products with prescription oral diflunisal. Exact preparation, dose and duration matter; other drugs and food exposures are not interchangeable.
Read the interaction guide →Oral aluminum-containing products with prescription oral diflunisal. Direct evidence is for aluminum hydroxide antacids, not every aluminum salt or exposure.
Read the interaction guide →Oral Ginkgo biloba products with prescription oral diflunisal. Exact preparation, dose and duration matter; other drugs and food exposures are not interchangeable.
Read the interaction guide →Oral Hypericum extracts with oral digoxin, with hyperforin content and repeated use explicitly relevant.
Read the interaction guide →Psyllium husk powder with oral digoxin; the original trial used a specific ispaghula formulation, not every husk preparation.
Read the interaction guide →Oral magnesium-containing antacids with oral digoxin tablets. Elemental nutrient categories, foods, other salts and injected digoxin are separate.
Read the interaction guide →Oral aluminum-containing antacids with oral digoxin tablets. Elemental nutrient categories, foods, other salts and injected digoxin are separate.
Read the interaction guide →E.arvense oral aerial-part preparations with digoxin; the study used a defined dry extract in healthy men.
Read the interaction guide →Oral vitamin D supplements with digoxin; guidance directly covers colecalciferol/D3, while high-calcium susceptibility is the physiological concern.
Read the interaction guide →Glycyrrhizin-containing oral Gan cao/licorice root or stolon preparations with digoxin. Processed rhizome formulas and deglycyrrhizinated products need separate identity assessment.
Read the interaction guide →Plantago ovata husk powder, not every fiber type; oral versus injected hydromorphone.
Read the interaction guide →Generic Radix et Rhizoma Valerianae does not identify species; evidence applies conditionally to confirmed Valeriana officinalis root/rhizome products.
Read the interaction guide →Piper methysticum beverages and extracts; preparation differences matter.
Read the interaction guide →CBD dose, formulation and route matter; hydromorphone immediate-release oral, extended-release and injected forms differ.
Read the interaction guide →Oral L-5-HTP, not dietary tryptophan; all medicines and supplements need consideration.
Read the interaction guide →Ordinary dietary fiber intake versus bulk-forming supplements or treatment of severe constipation.
Read the interaction guide →Oral synthetic delta-9 THC as dronabinol versus inhaled cannabis or other THC products; hydromorphone route/formulation boundaries.
Read the interaction guide →Oral melatonin; dose, release form and product content vary.
Read the interaction guide →Oral diltiazem with grapefruit flesh. Inspected clinical studies used juice and do not measure exact flesh effects or topical diltiazem interactions.
Read the interaction guide →Oral diltiazem with Hypericum perforatum products capable of CYP3A induction. Hyperforin content varies; a midazolam probe study is indirect evidence.
Read the interaction guide →Oral diltiazem with gugulipid, an extract linked in NLM terminology to Commiphora wightii/C.mukul. Evidence does not authenticate every whole-plant or resin product.
Read the interaction guide →Oral garlic supplements with oral dipyridamole tablets. Exact formulation, dose and duration matter; other antiplatelet medicines and other supplement preparations are not interchangeable.
Read the interaction guide →Oral Vaccinium myrtillus products with oral dipyridamole. Purified bilberry plus blackcurrant anthocyanins are not whole fruit, leaves or every extract.
Read the interaction guide →Oral Salvia miltiorrhiza root and rhizome preparations with oral dipyridamole. Injected isolated depside salts and unspecified multi-herb prescriptions are separate exposures.
Read the interaction guide →Oral ginger root powder with oral dipyridamole tablets. Exact formulation, dose and duration matter; other antiplatelet medicines and other supplement preparations are not interchangeable.
Read the interaction guide →Oral caffeine-containing guarana seed products before IV dipyridamole myocardial perfusion testing. This does not establish altered absorption or reduced benefit of oral dipyridamole antiplatelet treatment.
Read the interaction guide →Oral caffeine before IV dipyridamole myocardial perfusion testing. This does not establish altered absorption or reduced benefit of oral dipyridamole antiplatelet treatment.
Read the interaction guide →Oral Ginkgo biloba with oral dipyridamole tablets. Exact formulation, dose and duration matter; other antiplatelet medicines and other supplement preparations are not interchangeable.
Read the interaction guide →Oral Salvia miltiorrhiza preparations with oral dipyridamole. Injected isolated depside salts and unspecified multi-herb prescriptions are separate exposures.
Read the interaction guide →Asian Panax ginseng root and specific extracts, not every ginseng species or preparation. Fixed NovoLog Mix70/30 insulin scope.
Read the interaction guide →Oral Aloe vera gel; latex, whole leaf and topical gel differ. Medication evidence concerns the fixed70/30 premix.
Read the interaction guide →Opuntia ficus-indica steamed plant material versus dried capsules or concentrated extracts; medication scope is fixed NovoLog Mix70/30.
Read the interaction guide →Momordica charantia capsules; juice, food, seed and concentrated extracts differ. Fixed NovoLog Mix70/30 medication scope.
Read the interaction guide →Gymnema sylvestre leaf extract GS4; other powders, extracts and blends differ. NovoLog Mix70/30 contains two insulin components.
Read the interaction guide →Oral niacin, especially pharmacologic nicotinic acid; ordinary dietary vitamin B3 and nicotinamide differ. Fixed70/30 product contains protamine and soluble aspart.
Read the interaction guide →Applies to oral fosamprenavir regimens; source labeling concerns fosamprenavir-calcium products, with additional guidance for fosamprenavir/ritonavir.
Read the interaction guide →Oral doxycycline and oral iron preparations. The direct original study used ferrous sulfate; intravenous iron is not covered by that absorption result.
Read the interaction guide →Systemic doxycycline and oral preformed vitamin A such as retinol or retinyl esters. Isotretinoin and topical retinoids remain distinct medicines; beta-carotene and ordinary food intake are not automatically assigned the same toxicity profile.
Read the interaction guide →Oral doxycycline with magnesium-containing antacids or laxatives. Nutritional magnesium salts require explicit applicability assessment; injected magnesium and low blood magnesium are different questions.
Read the interaction guide →Oral doxycycline chloride 200 mg and zinc sulfate providing 45 mg zinc in the direct study. The evidence does not establish equivalence for every doxycycline or zinc formulation, or for multivitamins containing additional minerals.
Read the interaction guide →Oral doxycycline, with product-label evidence for hyclate tablets and calcium-containing antacids. Milk-study findings are contextual and are not an exact effect estimate for calcium supplements.
Read the interaction guide →Oral bismuth subsalicylate, including the studied liquid product, with oral doxycycline hyclate. Bismuth subcitrate and clinician-designed combination regimens are not interchangeable with this exposure.
Read the interaction guide →Grapefruit flesh, distinct from repeated juice intake, peel and concentrated extracts.
Read the interaction guide →Oral supplemental vitamin E; unspecified preparation in a multi-product surgical case, distinct from ordinary dietary vitamin E.
Read the interaction guide →Oral Allium sativum; food, powders and concentrated supplements distinguished.
Read the interaction guide →Oral Hypericum perforatum with sertraline hydrochloride tablets.
Read the interaction guide →Concentrated oral L-tryptophan; distinct from the other serotonin precursor and ordinary food protein.
Read the interaction guide →Citrus paradisi inventory mapped only conditionally to studied grapefruit juice; isolated extracts, rind and flesh are not established equivalents.
Read the interaction guide →Oral Hypericum perforatum products with simvastatin. The studies used specific herb products; other botanicals and other statins are not assumed equivalent.
Read the interaction guide →Oral red yeast rice supplements with simvastatin. Monacolin content and additional ingredients determine how closely a studied product matches a bottle.
Read the interaction guide →Oral simvastatin and grapefruit juice. Effects from a given juice preparation are not numeric estimates for all Citrus paradisi extracts.
Read the interaction guide →Oral simvastatin with niacin-containing products. Nicotinic acid, niacinamide and nutritional amounts require distinct interpretation.
Read the interaction guide →Oral terazosin with CoQ10 supplements; the inspected trial used 100 mg twice daily with unchanged background antihypertensive treatment.
Read the interaction guide →Oral terazosin and Crataegus monogyna. Human hawthorn studies used an incompletely authenticated leaf-and-flower extract or C.laevigata, a different species.
Read the interaction guide →Oral terazosin and supplemental L-arginine; oral gram-dose studies, not IV arginine or dietary protein.
Read the interaction guide →Oral Arctostaphylos uva-ursi leaf preparations, including tea and extracts. Evidence does not cover other plant parts or every mixed urinary product.
Read the interaction guide →Oral Allium sativum products with oral enalapril. Ordinary culinary garlic and aged, powdered or concentrated supplement products are distinct exposures.
Read the interaction guide →Oral Panax ginseng, including defined Korean red ginseng preparations, during oral enalapril treatment. Results are not automatically transferred to American ginseng, other species or multi-ingredient products.
Read the interaction guide →Oral berberine products with oral enalapril. Salt, formulation, dose and other active ingredients must be identified. Results with benazepril, amlodipine or mixed botanical products are not assigned to enalapril.
Read the interaction guide →Oral Beta vulgaris preparations with oral enalapril. The strongest relevant studies used nitrate-rich beetroot juice, not every beet product. A separately added nitrate supplement is a different exposure and is not silently included in this pair.
Read the interaction guide →Oral magnesium supplements, magnesium-containing antacids or laxatives with oral enalapril. Identify the salt, elemental amount and purpose. Intravenous magnesium and magnesium present only as a tablet excipient are outside this scope.
Read the interaction guide →Oral Crataegus monogyna products with oral enalapril. Species, plant part, extraction method and strength need to be identified. Evidence for other hawthorn species, mixed extracts or root products is not automatically applicable.
Read the interaction guide →Oral Hibiscus sabdariffa tea or extracts with oral enalapril. Tea, aqueous calyx extract and other plant parts are not dose-equivalent. Studies of captopril or lisinopril are not direct enalapril interaction evidence.
Read the interaction guide →Oral Olea europaea leaf extracts with oral enalapril. This does not describe olive oil as food, olive fruit, or every product with an olive-derived ingredient.
Read the interaction guide →Oral yohimbine during oral enalapril treatment. Yohimbe bark products may contain yohimbine, but their strength cannot be assumed to match a purified-dose study.
Read the interaction guide →Oral cascara bark from Frangula purshiana, synonymous with Rhamnus purshiana. Does not include Frangula alnus, senna, coffee-fruit cascara or unspecified multi-herb laxatives.
Read the interaction guide →Oral potassium supplements and potassium-containing salt substitutes during oral enalapril treatment. The concern is the potassium dose from all products, not a single brand or salt. This is not a blanket instruction to avoid potassium-containing foods.
Read the interaction guide →Oral Juniperus communis cone berries and their preparations. Findings do not cover concentrated essential oil or other Juniperus species.
Read the interaction guide →Oral omega-3 products with oral enalapril, focusing on fish oil supplying EPA and DHA. Evidence from fish oil is not automatically assigned to ALA, every algal product or a prescription omega-3 formulation.
Read the interaction guide →Oral glycyrrhizin-containing licorice root or root-and-rhizome products identified as Radix et Rhizoma Glycyrrhizae. The European assessment concerns roots and stolons of G. glabra, G. inflata or G. uralensis that contain glycyrrhizin. Species, processing, part and glycyrrhizin dose must still be checked. Deglycyrrhizinated licorice and topical preparations are excluded.
Read the interaction guide →Oral Allium sativum bulb extracts with oral enalapril. The trial used one aged, standardized bulb extract; other extraction methods and strengths are not assumed equivalent.
Read the interaction guide →Oral Ephedra sinica aerial-part preparations containing ephedrine alkaloids, including powdered ma-huang. Mixed supplements, alkaloid-free products, other Ephedra species and prescription ephedrine are not interchangeable.
Read the interaction guide →The effectiveness record covers oral systemic topiramate; the size and onset of the interaction are not quantified.
Read the interaction guide →Applies to oral systemic topiramate with pharmaceutical cannabidiol in refractory epilepsy, often alongside other antiseizure medicines.
Read the interaction guide →Arctostaphylos uva-ursi species entry; regulatory evidence concerns specified oral leaf preparations.
Read the interaction guide →Glycyrrhiza glabra, particularly glycyrrhizin-containing root preparations; deglycyrrhizinated products are not equivalent.
Read the interaction guide →Oral Hypericum perforatum with oral torsemide; topical oil and pure hypericin are separate exposures.
Read the interaction guide →Panax ginseng root and defined oral products; American ginseng, other species, mixtures, and red or white preparations should be distinguished.
Read the interaction guide →Rhamnus cathartica species entry; available exact botanical safety information concerns fruit ingestion. Frangula alnus/Rhamnus frangula and cascara are distinct.
Read the interaction guide →Oral Ephedra sinica containing ephedrine alkaloids; mixed caffeine products and alkaloid-free preparations are distinct.
Read the interaction guide →Herba Taraxaci herb-material entry; confirm species and parts. Fresh leaf extract and root-with-herb are not automatically the same product.
Read the interaction guide →Equisetum arvense aerial dry extract evidence; other horsetail species and blends are distinct.
Read the interaction guide →Potassium nutrient entry; dietary intake, oral replacement salts and intravenous treatment are distinct. This article does not prescribe a replacement dose.
Read the interaction guide →Juniperus communis species entry; regulatory evidence mainly concerns cone berries and defined oral extracts, not all oils or plant parts.
Read the interaction guide →Frangula alnus, also called Rhamnus frangula, dried bark and specified standardized oral preparations; not Rhamnus cathartica or cascara.
Read the interaction guide →Generic licorice root/rhizome entry. Confirm Glycyrrhiza species and glycyrrhizin content; EMA guidance covers roots of G. glabra, G. inflata and G. uralensis.
Read the interaction guide →Trivalent oral chromium supplements; picolinate trial evidence does not represent every salt or industrial hexavalent chromium.
Read the interaction guide →Asian Panax ginseng, including specific root-extract studies; American ginseng is a separate species.
Read the interaction guide →Dried Zingiber officinale rhizome powder, often sold as root powder; not all extracts, oils or isolated gingerols.
Read the interaction guide →Herba Taraxaci herbal material; salad exposure in the case does not identify every plant part, extract or root product.
Read the interaction guide →Oral niacin, especially pharmacologic nicotinic acid; dietary vitamin B3 and nicotinamide are different exposures.
Read the interaction guide →Oral willow bark medicinal preparations containing salicin. Salicin is not treated as aspirin, and results from a studied extract are not automatically assigned to all Salix products.
Read the interaction guide →Oral chaparral reported as Larrea tridentata; other species, purified constituents and topical preparations are outside this evidence.
Read the interaction guide →Oral Hypericum perforatum with valproate. Class-wide regulatory advice specifically addresses epilepsy; other indications require separate clinical review.
Read the interaction guide →Generic valerian root/rhizome node. Apply V. officinalis evidence only when that species and relevant plant part are verified; other species and blends are not automatically equivalent.
Read the interaction guide →Oral Withania somnifera preparations. Sensoril aqueous-extract findings do not establish the same effects for every root, leaf or mixed extract.
Read the interaction guide →Borage seed oil from Borago officinalis. Evidence about leaves, flowers or other oils is not treated as seed-oil evidence.
Read the interaction guide →Concentrated Camellia sinensis leaf extract. Findings from the studied extract are not treated as evidence about ordinary brewed tea or a universal safe-dose cutoff.
Read the interaction guide →Symphytum officinale root oral-toxicity information, with indirect leaf-ingestion case context of unconfirmed exact species. Specified topical medicinal preparations are a different exposure.
Read the interaction guide →Oral Piper methysticum beverages and extracts; extraction method, plant material and co-ingredients matter.
Read the interaction guide →Levocarnitine (L-carnitine), with oral supplementation for selected patients distinguished from clinician-administered IV treatment in toxicity. Acetyl-L-carnitine and D-carnitine are not substituted.
Read the interaction guide →Oral preparations reported as Teucrium polium in human cases. Findings are not substituted from Teucrium chamaedrys and do not establish equivalence across extracts or topical products.
Read the interaction guide →Oral magnesium supplements distinguished from multi-ingredient antacids and from magnesium valproate, a medication salt. Historical Maalox preparations cannot be assumed identical to current Maalox Plus or to an isolated magnesium salt.
Read the interaction guide →Oral biotin (vitamin B7) during valproate treatment. Blood biotin and biotinidase activity are different measurements; enzyme changes are not a diagnosis of dietary deficiency.
Read the interaction guide →Oral Passiflora incarnata herb preparations; do not extend to other species, passion fruit or every combination product.
Read the interaction guide →Ginkgo biloba leaf preparations and an incompletely characterized supplement exposure in a case involving Depakote. Seed-toxin evidence is not assumed to establish leaf-extract effects.
Read the interaction guide →Oral melatonin with oral valproate, sodium valproate or valproic acid in specified trials; release form, age, indication and dose limit generalization.
Read the interaction guide →Oral calcium intake and supplements during long-term oral valproate treatment. Calcium valproate is a medication salt, not calcium supplementation.
Read the interaction guide →Oral vitamin D during long-term oral valproate treatment. The inspected intervention does not identify D2 versus D3; active vitamin D medicines are not interchangeable with nutritional vitamin D.
Read the interaction guide →Oral folic acid before conception and during pregnancy in people of childbearing potential taking valproate. Folic acid is not automatically interchangeable with folinic acid or methylfolate.
Read the interaction guide →Oral L-glutamine supplements with valproate. Endogenous blood or brain glutamine, glutamate, glutamine synthetase disorders and cell-culture glutamine are not oral supplementation exposures.
Read the interaction guide →The relevant clinical evidence concerns oil of wintergreen or methyl salicylate formulations, not authenticated whole Gaultheria procumbens. Oral ingestion and normal topical application are not equivalent exposures.
Read the interaction guide →Matricaria chamomilla species entry; oral German chamomile tea and extracts are distinct preparations. Roman chamomile and topical use are not equivalent.
Read the interaction guide →Oral Valeriana officinalis root preparations; other species, extracts and mixed products remain distinct.
Read the interaction guide →Oral Hypericum perforatum extracts; hyperforin content and the exact medication metabolism matter.
Read the interaction guide →Radix et Rhizoma Valerianae has unresolved species identity; Valeriana officinalis evidence applies only after a match is confirmed.
Read the interaction guide →Oral Withania somnifera preparations; the cited sleep trial used a specific root extract, not arbitrary leaf or mixed products.
Read the interaction guide →Oral Piper methysticum; extract, dose and other sedatives must be identified.
Read the interaction guide →Oral melatonin; prolonged-release product guidance is distinct from immediate-release supplements.
Read the interaction guide →Citrus paradisi fruit extract with unspecified composition; grapefruit juice, seeds and purified constituents are distinct exposures.
Read the interaction guide →Route matters: transdermal estradiol may be less affected than oral estradiol, but the difference is not quantified.
Read the interaction guide →This evidence concerns oral St. John's wort extracts and oral tacrolimus. Both immediate-release and prolonged-release tacrolimus have shown an interaction; individual herbal extracts can differ.
Read the interaction guide →Curcumin is a constituent of turmeric, but turmeric food, mixed turmeric extracts and isolated or absorption-enhanced curcumin supplements are different exposures. The available studies do not establish equivalence among them.
Read the interaction guide →This article concerns oral berberine with oral tacrolimus. Results from cyclosporine, goldenseal or other plant mixtures cannot establish the effect of this exact combination.
Read the interaction guide →The strongest study used prescription EPIDIOLEX and oral PROGRAF. Its numerical result cannot be assumed for a low-dose gummy, a different oil, an inhaled product or a topical preparation.
Read the interaction guide →The report involved cranberry juice extract capsules, not a measured serving of juice or whole cranberries. The product's precise composition and botanical species were not verified, which limits its application to Vaccinium macrocarpon.
Read the interaction guide →This advice concerns oral tacrolimus and aluminum hydroxide antacids. The measured interaction involved combined magnesium and aluminum hydroxide, so it does not give an effect size for aluminum hydroxide alone.
Read the interaction guide →This concerns potassium-containing supplements and salt substitutes. Whether you need a supplement or a dietary restriction depends on your blood tests, kidney function and other medicines; there is no single intake target for every tacrolimus user.
Read the interaction guide →Human studies mainly measured grapefruit juice. The advice to avoid both juice and whole grapefruit comes from tacrolimus product information; individual juice products can have very different effects.
Read the interaction guide →Schisandra chinensis and Schisandra sphenanthera are distinct species. Wuzhi products studied with tacrolimus commonly contain S. sphenanthera extract; neither a shared common name nor a similar constituent makes the extracts interchangeable.
Read the interaction guide →Applies to oral bupropion and oral St. John's wort products; formulations and indications have different dosing constraints.
Read the interaction guide →Oral Hypericum perforatum, commonly called St. John’s wort, with oral lithium carbonate. The label names the herb but does not establish a safe extract, constituent threshold or risk estimate for each preparation.
Read the interaction guide →Oral tripotassium citrate; the inspected preparation is its monohydrate extended-release prescription tablet. The concern is conditional on a clinically relevant alkalinizing exposure, not every trace food-additive use.
Read the interaction guide →Sodium chloride as dietary salt or an oral salt supplement during lithium carbonate treatment. Sodium-containing citrate/bicarbonate products and potassium-based salt substitutes have distinct compositions and are not interchangeable.
Read the interaction guide →Oral sodium citrate; the inspected alkalinizing product is a sodium citrate dihydrate/citric acid solution, not isolated anhydrous trisodium citrate. The concern is conditional on a clinically relevant alkalinizing exposure, not every trace food-additive use.
Read the interaction guide →Habitual oral caffeine from drinks or supplements with oral lithium carbonate. The direct case used sustained-action carbonate; an acute renal-marker study does not establish equal effects across formulations or caffeine doses.
Read the interaction guide →Oral ripe dry or powdered Plantago afra seed, within the P. afra/P. indica seed monograph. P. ovata husk, other plant parts and generic psyllium mixtures are not automatically equivalent.
Read the interaction guide →Oral Juniperus communis fruit extract, limited to preparation-specific berry evidence; extraction solvent, ratio and dose matter. Essential oil, other plant parts and other juniper species are not automatically equivalent.
Read the interaction guide →Equisetum arvense oral aerial-part extract, distinguished from E. hyemale, other horsetail species, combination diuretic products and uncharacterized teas.
Read the interaction guide →Juniperus communis is a species-level entry. The inspected regulatory evidence concerns its pseudo-fruit, commonly called berries, and defined oral preparations. Essential oil, other plant parts and other juniper species are not automatically equivalent.
Read the interaction guide →Radix et Rhizoma Glycyrrhizae (Gan cao) oral preparations. Inspected EMA evidence concerns glycyrrhizin-containing roots and stolons of G. glabra, G. inflata and G. uralensis; exact processing and composition must be verified. Deglycyrrhizinated licorice is not assumed equivalent.
Read the interaction guide →Generic root/rhizome node; confirm Valeriana officinalis species before applying its guidance.
Read the interaction guide →Piper methysticum beverages or extracts; strength and co-ingredients vary.
Read the interaction guide →Oral L-5-hydroxytryptophan supplements, not routine protein foods.
Read the interaction guide →Oral melatonin with specific timing and dose; not transdermal melatonin or all prolonged-release preparations.
Read the interaction guide →Oral S-adenosylmethionine supplements; formulations and doses differ.
Read the interaction guide →Concentrated oral L-tryptophan, not ordinary dietary protein.
Read the interaction guide →Oral fludrocortisone with glycyrrhizin-containing Glycyrrhiza glabra root/stolon preparations. Deglycyrrhizinated products and uncharacterized extracts differ.
Read the interaction guide →Sodium chloride intake or supplements during oral fludrocortisone acetate treatment. Adrenal mineralocorticoid replacement and orthostatic indications require individualized salt plans.
Read the interaction guide →Oral fludrocortisone with magnesium. Relevant studies used particular antacid mixtures and other corticosteroids; elemental nutrient entries are not identical to antacid formulations.
Read the interaction guide →Oral fludrocortisone with aluminum. Relevant studies used particular antacid mixtures and other corticosteroids; elemental nutrient entries are not identical to antacid formulations.
Read the interaction guide →Potassium intake and replacement during oral fludrocortisone treatment. Monitoring and replacement depend on dose, indication, kidney function, other medicines and test results.
Read the interaction guide →Vitamin D during oral fludrocortisone acetate mineralocorticoid replacement. Concurrent glucocorticoid dose and bone risk must be assessed separately.
Read the interaction guide →Supplemental vitamin E with fluoxetine; the reported case used a multivitamin containing 50 IU, not a high-dose isolated vitamin E regimen.
Read the interaction guide →Oral Allium sativum supplements; raw food garlic, commercial tablets and extracts differ.
Read the interaction guide →Oral Hypericum perforatum with fluoxetine capsules; exact herb formulation and other serotonergic medicines matter.
Read the interaction guide →Oral L-5-HTP requested; the trial’s reported 5-hydroxytryptophan product has incomplete exact isomer and preparation documentation.
Read the interaction guide →Oral supplemental zinc with fluoxetine; distinguish elemental zinc amount and formulation from total salt weight.
Read the interaction guide →Oral SAMe, distinct from injected treatment and dietary methionine.
Read the interaction guide →Concentrated oral L-tryptophan, distinct from usual protein foods and L-5-HTP.
Read the interaction guide →Oral fluphenazine with the exact supplement preparation described.
Read the interaction guide →Oral fluphenazine with the exact supplement preparation described.
Read the interaction guide →Oral fluphenazine with the exact supplement preparation described.
Read the interaction guide →Oral fluphenazine with the exact supplement preparation described.
Read the interaction guide →Oral fluphenazine with the exact supplement preparation described.
Read the interaction guide →Oral fluphenazine with the exact supplement preparation described.
Read the interaction guide →Oral fluphenazine with the exact supplement preparation described.
Read the interaction guide →Oral willow bark products with oral flurbiprofen tablets. Medicinal Salix bark guidance has defined preparation scope; exact species and salicin content must be checked.
Read the interaction guide →Oral Angelica sinensis with oral flurbiprofen tablets. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable.
Read the interaction guide →Oral vitamin E supplements with oral flurbiprofen tablets. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable.
Read the interaction guide →Oral garlic supplements with oral flurbiprofen tablets. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable.
Read the interaction guide →Oral Panax ginseng with oral flurbiprofen tablets. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable.
Read the interaction guide →Oral ginger root powder with oral flurbiprofen tablets. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable.
Read the interaction guide →Oral evening primrose oil during prescription oral flurbiprofen treatment. Defined oil and GLA content differ from isolated GLA and other oils.
Read the interaction guide →Oral potassium replacement with oral flurbiprofen tablets. Potassium chloride solution evidence supplies a regulatory class bridge; dietary potassium and other routes are separate.
Read the interaction guide →Evidence concerns the alendronate active moiety in oral alendronate sodium. The label explicitly expresses sodium-salt strength as the free-acid equivalent; this does not transfer recommendations to another bisphosphonate or injectable route.
Read the interaction guide →Evidence concerns the alendronate active moiety in oral alendronate sodium. The label explicitly expresses sodium-salt strength as the free-acid equivalent; this does not transfer recommendations to another bisphosphonate or injectable route.
Read the interaction guide →Evidence concerns the alendronate active moiety in oral alendronate sodium. The label explicitly expresses sodium-salt strength as the free-acid equivalent; this does not transfer recommendations to another bisphosphonate or injectable route.
Read the interaction guide →Evidence concerns the alendronate active moiety in oral alendronate sodium. The label explicitly expresses sodium-salt strength as the free-acid equivalent; this does not transfer recommendations to another bisphosphonate or injectable route.
Read the interaction guide →Evidence concerns the alendronate active moiety in oral alendronate sodium. The label explicitly expresses sodium-salt strength as the free-acid equivalent; this does not transfer recommendations to another bisphosphonate or injectable route.
Read the interaction guide →Evidence concerns the alendronate active moiety in oral alendronate sodium. The label explicitly expresses sodium-salt strength as the free-acid equivalent; this does not transfer recommendations to another bisphosphonate or injectable route.
Read the interaction guide →Evidence concerns the alendronate active moiety in oral alendronate sodium. The label explicitly expresses sodium-salt strength as the free-acid equivalent; this does not transfer recommendations to another bisphosphonate or injectable route.
Read the interaction guide →Oral trivalent chromium supplements; studied chromium picolinate differs from other salts and dietary intake.
Read the interaction guide →Oral Hypericum perforatum preparations; inducing potential varies with product composition.
Read the interaction guide →Asian Panax ginseng root and defined extracts, not American ginseng.
Read the interaction guide →Defined Ginkgo biloba leaf extract EGb 761; not seeds, raw leaf or all commercial extracts.
Read the interaction guide →Momordica charantia capsules versus food, juice, seed and other extracts.
Read the interaction guide →Defined fenugreek capsules versus seed foods, teas and other extracts; glyburide is also called glibenclamide.
Read the interaction guide →Trivalent supplemental chromium, especially picolinate evidence; elemental dose and salt matter. Direct trial used glipizide GITS extended release.
Read the interaction guide →Oral Allium sativum supplements; garlic oils, aged extracts, powder, food portions and blends are not interchangeable.
Read the interaction guide →Hypericum perforatum oral products with glipizide; extraction and constituent content matter. Gliclazide, glimepiride and glyburide are distinct medicines.
Read the interaction guide →Asian Panax ginseng products; root processing and extraction differ, and Panax quinquefolius is a separate species.
Read the interaction guide →Dried Zingiber officinale rhizome powder, commonly called root powder; not isolated gingerols, essential oil or all extracts.
Read the interaction guide →Opuntia ficus-indica exact species; steamed nopal, dried capsules, fruit and extracts are different exposures.
Read the interaction guide →Trigonella foenum-graecum seed and extract supplements; culinary amounts, whole seed and hydroalcoholic extracts are not equivalent.
Read the interaction guide →Oral magnesium hydroxide antacid with single-dose conventional glipizide; not all magnesium salts, magnesium deficiency treatment or extended-release products.
Read the interaction guide →Niacin forms distinguished: label interaction concerns nicotinic acid, especially pharmacologic use; ordinary food intake and nicotinamide are not interchangeable.
Read the interaction guide →Evidence concerns continuous transdermal nitroglycerin with oral folic acid for about one week in small healthy-male study groups.
Read the interaction guide →Oral doxazosin with glycyrrhizin-containing Glycyrrhiza glabra root or stolon products. Deglycyrrhizinated licorice and other plant parts are not assumed equivalent.
Read the interaction guide →Oral doxazosin with Allium sativum supplements. The human evidence concerns a specific aged bulb extract, not ordinary food portions or every garlic oil or powder.
Read the interaction guide →Oral doxazosin and Crataegus monogyna. Human hawthorn studies used an incompletely authenticated leaf-and-flower extract or C.laevigata, a different species.
Read the interaction guide →Trivalent oral chromium supplements; picolinate trial evidence does not represent every salt or industrial hexavalent chromium.
Read the interaction guide →Asian Panax ginseng, including specific root-extract studies; American ginseng is a separate species.
Read the interaction guide →Oral Aloe vera inner-leaf gel evidence; latex, whole leaf, topical gel and blends are different exposures.
Read the interaction guide →Dried Zingiber officinale rhizome powder, often sold as root powder; not all extracts, oils or isolated gingerols.
Read the interaction guide →Oral DL racemate; R-alpha-lipoic acid and unspecified ALA products are not automatically equivalent. Subcutaneous or supervised intravenous insulin aspart is distinct from endogenous insulin.
Read the interaction guide →Momordica charantia oral capsule evidence; food, juice, seed and concentrated extracts differ.
Read the interaction guide →Oral D-glucose/dextrose for appropriate low-glucose treatment versus supervised intravenous glucose; not a routine nutrient replacement or a substitute for an individualized meal plan.
Read the interaction guide →Authenticated fenugreek seeds in traditional preparations; food seasoning differs from medicinal amounts. Premixed insulin reports are indirect for pure insulin aspart.
Read the interaction guide →Oral niacin, especially high-dose nicotinic acid; nicotinamide and Fiasp’s niacinamide excipient are different exposures.
Read the interaction guide →Arctostaphylos uva-ursi species entry; available regulatory guidance concerns specified oral leaf preparations.
Read the interaction guide →Oral Hypericum perforatum with lithium citrate oral solution; other serotonergic medicines and product composition matter.
Read the interaction guide →Oral sodium bicarbonate, including medicinal antacid or alkalinizing exposure; intravenous use is outside this article.
Read the interaction guide →Oral potassium citrate; label formulation is tripotassium citrate monohydrate extended-release, not every supplement dose.
Read the interaction guide →Oral sodium citrate; supporting label combines sodium citrate dihydrate with citric acid. Food-additive exposure is not automatically medicinal alkali exposure.
Read the interaction guide →Oral L-5-hydroxytryptophan; not interchangeable with tryptophan. Lithium carbonate challenge findings are indirect for citrate.
Read the interaction guide →Oral caffeine from drinks or supplements with lithium citrate; carbonate case evidence is indirect through the shared lithium ion.
Read the interaction guide →Plantago afra seeds covered by the EMA seed monograph; P. ovata husk and unspecified extracts require their own product guidance.
Read the interaction guide →Herba Taraxaci is a herb-material entry. Confirm species, plant parts and preparation; neither dried root alone nor root-with-herb is automatically equivalent.
Read the interaction guide →Equisetum arvense, particularly the studied aerial dry extract. Equisetum hyemale and multi-herb products are not interchangeable.
Read the interaction guide →Juniperus communis species entry; strongest regulatory material concerns cone berries and specified oral extracts, not every plant part or oil.
Read the interaction guide →Dried dandelion root; regulatory evidence assumes confirmed Taraxacum officinale root. Fresh leaf extract is distinct.
Read the interaction guide →Petroselinum crispum species entry. Parsley leaf tea is not seed oil, a concentrated extract or a multi-herb product; abstract-level species characterization is incomplete.
Read the interaction guide →Angelica sinensis oral product; no automatic transfer from warfarin, aspirin, other Angelica species or multi-herb formulas.
Read the interaction guide →Oral supplemental vitamin E, primarily alpha-tocopherol evidence, with injected unfractionated heparin; not vitamin E-coated dialysis membranes or topical combination creams.
Read the interaction guide →Oral Allium sativum supplements with injected unfractionated heparin; food amounts, oils, aged extracts and other preparations are not identical.
Read the interaction guide →Oral Panax ginseng products with injected unfractionated heparin; American ginseng, red/white preparations and mixed formulas are not interchangeable.
Read the interaction guide →Radix et Rhizoma Salviae Miltiorrhizae, confirmed Salvia miltiorrhiza root/rhizome oral product. Injectable danshen, isolated constituents and multi-herb formulas are distinct.
Read the interaction guide →Zingiber officinale dried rhizome powder, commonly sold as root powder; not fresh juice, oil or a concentrated extract. Heparin means injected unfractionated heparin.
Read the interaction guide →Oral mixed EPA+DHA fish-oil products with injected unfractionated heparin; isolated high-dose EPA, other oils and different formulations require separate assessment.
Read the interaction guide →Oral Ginkgo biloba leaf extracts or leaf powder with injected unfractionated heparin; seeds and injected ginkgo combination medicines are outside this scope.
Read the interaction guide →Oral Tanacetum parthenium preparations; capsule dose, extract standardization and fresh-leaf exposure are distinct.
Read the interaction guide →Potassium nutrient exposure with parenteral unfractionated heparin; dose, salt formulation and total intake matter. No blanket restriction of all potassium-containing foods.
Read the interaction guide →Genus-level Ganoderma entry; the studied G. lucidum capsules are only one preparation. Extracts, spores and other species must be distinguished.
Read the interaction guide →Applies to oral hydrochlorothiazide; risk depends on calcium and vitamin D intake, kidney function and conditions affecting calcium regulation.
Read the interaction guide →Applies to oral hydrochlorothiazide under an individualized treatment plan, including any potassium-sparing or other potassium-raising medicines.
Read the interaction guide →The trial studied vitamin D3 for three months in adults taking oral hydrochlorothiazide, excluding people with kidney disease, high calcium or calcium-metabolism disorders.
Read the interaction guide →Applies to oral hydrochlorothiazide; dietary sodium restriction, dilutional low sodium and actual salt depletion require different decisions.
Read the interaction guide →Oral hydrocortisone tablets with grapefruit flesh. Other plant parts, extracts, injected steroids and topical hydrocortisone are not equivalent.
Read the interaction guide →Oral hydrocortisone with glycyrrhizin-containing Glycyrrhiza glabra root/stolon preparations. Deglycyrrhizinated products and uncharacterized extracts differ.
Read the interaction guide →Adequate calcium intake during oral hydrocortisone treatment, especially prolonged systemic glucocorticoid exposure. Nutritional adequacy is not automatic need for a supplement or evidence of impaired tablet absorption.
Read the interaction guide →Potassium intake and replacement during oral hydrocortisone treatment. Monitoring and replacement depend on dose, indication, kidney function, other medicines and test results.
Read the interaction guide →Adequate vitamin D intake during oral hydrocortisone treatment, especially prolonged systemic glucocorticoid exposure. Nutritional adequacy is not automatic need for a supplement or evidence of impaired tablet absorption.
Read the interaction guide →Oral hydrocortisone tablets with grapefruit (Citrus paradisi) fruit/juice. Other plant parts, extracts, injected steroids and topical hydrocortisone are not equivalent.
Read the interaction guide →Oral Curcuma longa with oral prescription ibuprofen tablets. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable.
Read the interaction guide →Oral vitamin E supplements with oral prescription ibuprofen tablets. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable.
Read the interaction guide →Oral garlic supplements with oral prescription ibuprofen tablets. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable.
Read the interaction guide →Oral Panax ginseng with oral prescription ibuprofen tablets. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable.
Read the interaction guide →Oral ginger root powder with oral prescription ibuprofen tablets. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable.
Read the interaction guide →Oral Ginkgo biloba with oral prescription ibuprofen tablets. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable.
Read the interaction guide →Oral potassium replacement with oral prescription ibuprofen tablets. Potassium chloride solution evidence supplies a regulatory class bridge; dietary potassium and other routes are separate.
Read the interaction guide →Oral Hypericum perforatum and imipramine; UK hydrochloride solution warning is pharmacodynamic context, not a formulation dose bridge.
Read the interaction guide →Radix et Rhizoma Valerianae species unresolved; V. officinalis evidence is conditional on confirmation.
Read the interaction guide →Oral Piper methysticum; extract, amount and other sedatives are relevant.
Read the interaction guide →Atropa belladonna products with active alkaloid exposure; whole plant, concentrated extracts and highly diluted products are not equivalent.
Read the interaction guide →Oral L-5-hydroxytryptophan; benserazide-assisted treatment and unidentified hydroxytryptophan letter exposure are distinct.
Read the interaction guide →Oral imipramine with Circadin prolonged-release melatonin; other formulations and doses have not been shown equivalent.
Read the interaction guide →Concentrated oral L-tryptophan; a nicotinamide-containing research regimen is different from ordinary food protein.
Read the interaction guide →Camellia sinensis tea; laboratory tannins and brewed tea are not equivalent to every extract.
Read the interaction guide →Oral coenzyme Q10 (ubidecarenone) with indapamide. Evidence from combination supplements, other quinones or unspecified antihypertensive regimens is not exact-pair evidence.
Read the interaction guide →Allium sativum oral supplements, with evidence limited to a specified aged garlic bulb extract. Raw garlic, food amounts and other extracts are not equivalent.
Read the interaction guide →Oral magnesium supplementation during indapamide treatment. Magnesium chloride in the original trial is not proof for every magnesium salt, dose or indication.
Read the interaction guide →Crataegus monogyna oral products, distinguished from C. laevigata, unidentified hawthorn species and fruit versus leaf-and-flower preparations.
Read the interaction guide →Senna alexandrina: specified oral pod preparations in the inspected monograph. Leaf products and combinations require their own formulation review.
Read the interaction guide →Oral calcium supplements with indapamide. Calcium salts differ in elemental calcium content; dietary calcium and combination calcium-vitamin D products are distinct exposures.
Read the interaction guide →Frangula purshiana, called Rhamnus purshiana in the EMA monograph: specified oral cascara bark preparations, not Frangula alnus.
Read the interaction guide →Adequate dietary potassium and clinician-directed oral potassium replacement during indapamide treatment. Potassium salts and potassium-containing combination products require individual review.
Read the interaction guide →Oral vitamin D2 or D3 with indapamide, distinguished from calcium-vitamin D combination supplements and active vitamin D analogues. The co-use case did not specify the vitamin D form or dose.
Read the interaction guide →Radix et Rhizoma Glycyrrhizae (Gan cao), with concern limited to glycyrrhizin-containing oral licorice preparations. Food licorice, root/stolon preparations and processed multi-herb products are not exact dose equivalents.
Read the interaction guide →Oral vitamin E supplements with oral meclofenamate sodium capsules. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable.
Read the interaction guide →Oral garlic supplements with oral meclofenamate sodium capsules. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable.
Read the interaction guide →Oral iron tablets with oral meclofenamate sodium, explicitly bridged to meclofenamate IN. Dietary iron, liquid formulations and intravenous iron are distinct exposures.
Read the interaction guide →Oral Panax ginseng with oral meclofenamate sodium capsules. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable.
Read the interaction guide →Oral ginger root powder with oral meclofenamate sodium capsules. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable.
Read the interaction guide →Oral Salix alba products with oral meclofenamate sodium capsules. Medicinal Salix bark guidance has defined preparation scope; exact species and salicin content must be checked.
Read the interaction guide →Oral Ginkgo biloba with oral meclofenamate sodium capsules. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable.
Read the interaction guide →Oral feverfew with oral meclofenamate sodium capsules. Exact formulation, dose and duration matter; other NSAIDs and other supplement preparations are not interchangeable.
Read the interaction guide →Generic root/rhizome node; confirm the botanical species.
Read the interaction guide →Piper methysticum beverages/extracts; product strengths vary.
Read the interaction guide →Cannabidiol products; prescription purified oral CBD, retail oils, THC-containing mixtures and topical products are not equivalent.
Read the interaction guide →Oral L-5-hydroxytryptophan supplements.
Read the interaction guide →Oral melatonin; dose and release vary.
Read the interaction guide →Oral S-adenosylmethionine preparations.
Read the interaction guide →Cannabis sativa preparations with variable THC/CBD, route and dose; hemp foods and topical preparations are different exposures.
Read the interaction guide →Oral Hypericum perforatum extracts; hyperforin content and repeated exposure matter.
Read the interaction guide →Radix et Rhizoma Valerianae remains species-ambiguous; V. officinalis study applies only to the identified extract.
Read the interaction guide →Oral Withania somnifera; root-extract trial does not establish all leaf/root or mixture effects.
Read the interaction guide →Oral Piper methysticum; dose, extract and other CNS depressants matter.
Read the interaction guide →Oral cannabidiol, with strongest safety information from prescription purified CBD; not every consumer concentration, route or THC-containing product.
Read the interaction guide →Oral Passiflora incarnata aerial-part preparations; other species and mixtures are distinct.
Read the interaction guide →Oral melatonin with alprazolam; supervised perioperative immediate-dose studies differ from prolonged-release labels and chronic home use.
Read the interaction guide →Cannabis sativa with defined cannabinoid content; oral THC/CBD extracts are distinct from inhaled products, hempseed food and products without meaningful cannabinoid exposure.
Read the interaction guide →Valeriana officinalis root and rhizome preparations. Taken orally with oral isocarboxazid tablets; other species and preparations are not interchangeable.
Read the interaction guide →Oral Cytisus scoparius preparations containing tyramine. Plant part and extraction matter; other broom species and purified alkaloids are distinct exposures.
Read the interaction guide →Oral Hypericum perforatum preparations, including St. John’s wort extracts. Product composition varies. This does not cover topical preparations.
Read the interaction guide →Oral Camellia Sinensis Leaf Extract; caffeine amount and extraction method must be known. This assessment does not cover topical tea products.
Read the interaction guide →Piper methysticum beverages and extracts; preparations vary. Taken orally with oral isocarboxazid tablets; other species and preparations are not interchangeable.
Read the interaction guide →Oral L-tyrosine supplements with oral isocarboxazid. Food protein and tyrosine contained in parenteral nutrition are different exposures.
Read the interaction guide →Oral Paullinia cupana caffeine-containing preparations, usually seed products. The caffeine content of an unidentified formulation cannot be inferred from the name alone.
Read the interaction guide →Caffeine in any oral source, including drinks, foods and supplements, with oral isocarboxazid. The label does not define an exact safe daily amount.
Read the interaction guide →Oral Ephedra sinica stem or branch preparations containing ephedrine-type alkaloids. Root, other species, purified ephedrine salts and purported alkaloid-free products are not interchangeable.
Read the interaction guide →Oral L-tryptophan supplements with oral isocarboxazid. This does not cover normal dietary protein or 5-hydroxytryptophan, which is a distinct substance.
Read the interaction guide →Cannabis sativa is a broad identity covering very different products. The inspected human trial used vaporized cannabinoid-containing cannabis, not oral hemp seed, hemp oil, CBD supplements or topical products.
Read the interaction guide →Oral L-phenylalanine supplements with oral isocarboxazid. The label names phenylalanine without specifying stereochemistry; applying this precaution to supplemental L-phenylalanine is reasonable, but D-phenylalanine and DL mixtures are not independently assessed.
Read the interaction guide →Oral Curcuma longa with oral prasugrel hydrochloride tablets. Exact formulation, dose and duration matter; other antiplatelet medicines and other supplement preparations are not interchangeable.
Read the interaction guide →Oral vitamin E supplements with oral prasugrel hydrochloride tablets. Exact formulation, dose and duration matter; other antiplatelet medicines and other supplement preparations are not interchangeable.
Read the interaction guide →Oral garlic supplements with oral prasugrel hydrochloride tablets. Exact formulation, dose and duration matter; other antiplatelet medicines and other supplement preparations are not interchangeable.
Read the interaction guide →Oral Hypericum perforatum preparations with oral prasugrel hydrochloride tablets. Hyperforin content, repeated exposure and the exact drug matter.
Read the interaction guide →Oral Panax ginseng with oral prasugrel hydrochloride tablets. Exact formulation, dose and duration matter; other antiplatelet medicines and other supplement preparations are not interchangeable.
Read the interaction guide →Oral ginger root powder with oral prasugrel hydrochloride tablets. Exact formulation, dose and duration matter; other antiplatelet medicines and other supplement preparations are not interchangeable.
Read the interaction guide →Oral fish oil containing EPA and DHA with oral prasugrel hydrochloride tablets. Purified EPA prescriptions, ALA and all omega-3 doses are not interchangeable.
Read the interaction guide →Oral Ginkgo biloba with oral prasugrel hydrochloride tablets. Exact formulation, dose and duration matter; other antiplatelet medicines and other supplement preparations are not interchangeable.
Read the interaction guide →Applies to oral systemic deferasirox with concentrated caffeine supplements.
Read the interaction guide →Oral labetalol with the exact supplement preparation described below.
Read the interaction guide →Oral labetalol with the exact supplement preparation described below.
Read the interaction guide →Oral labetalol with the exact supplement preparation described below.
Read the interaction guide →Oral labetalol with the exact supplement preparation described below.
Read the interaction guide →Oral labetalol with the exact supplement preparation described below.
Read the interaction guide →Oral labetalol with the exact supplement preparation described below.
Read the interaction guide →Radix et Rhizoma Valerianae has unresolved species identity; Valeriana officinalis evidence applies only after a match is confirmed.
Read the interaction guide →Oral Withania somnifera preparations; the cited sleep trial used a specific root extract, not arbitrary leaf or mixed products.
Read the interaction guide →Oral Piper methysticum; extract, dose and other sedatives must be identified.
Read the interaction guide →Oral Humulus lupulus female-inflorescence preparations; not all plant parts or blends.
Read the interaction guide →Oral Passiflora incarnata; original case also involved Valeriana officinalis, and specific product doses are unavailable in the abstract.
Read the interaction guide →Oral lorazepam tablets and oral melatonin; enteral ICU protocols and injected lorazepam studies are distinct contexts.
Read the interaction guide →Oral pregnenolone supplements; pregnenolone sulfate, pregnanolone, allopregnanolone and other steroid derivatives are distinct substances.
Read the interaction guide →Oral meclizine with the specific preparation described below.
Read the interaction guide →Oral meclizine with the specific preparation described below.
Read the interaction guide →Oral meclizine with the specific preparation described below.
Read the interaction guide →Oral meclizine with the specific preparation described below.
Read the interaction guide →Oral meclizine with the specific preparation described below.
Read the interaction guide →Oral meclizine with the specific preparation described below.
Read the interaction guide →Oral meclizine with the specific preparation described below.
Read the interaction guide →Oral meclizine with the specific preparation described below.
Read the interaction guide →Oral Curcuma longa product with subcutaneous dalteparin sodium; whole-herb products, isolated curcumin and enhanced-absorption formulations are not interchangeable.
Read the interaction guide →Oral potassium chloride with subcutaneous dalteparin sodium. Potassium chloride supplies potassium; sodium in the injection is a separate constituent, not the cause of this potassium-load interaction.
Read the interaction guide →Oral supplemental vitamin E, mainly alpha-tocopherol evidence, with subcutaneous dalteparin sodium; not vitamin E-coated dialysis devices or topical products.
Read the interaction guide →Oral Allium sativum supplements with subcutaneous dalteparin sodium; food amounts, oils, aged extracts and other preparations are not identical.
Read the interaction guide →Oral Panax ginseng products with subcutaneous dalteparin sodium; American ginseng, red/white preparations and mixed formulas are not interchangeable.
Read the interaction guide →Zingiber officinale dried rhizome powder, commonly sold as root powder; not fresh juice, oil or a concentrated extract. Dalteparin means subcutaneous dalteparin sodium.
Read the interaction guide →Oral mixed EPA+DHA fish-oil products with subcutaneous dalteparin sodium; isolated high-dose EPA, other oils and different formulations require separate assessment. Fish oil already contains omega-3 fatty acids; adding another omega-3 product changes total exposure and is not a separate proven interaction.
Read the interaction guide →Oral Ginkgo biloba leaf extracts or leaf powder with subcutaneous dalteparin sodium; seeds and injected ginkgo combination medicines are outside this scope.
Read the interaction guide →Oral potassium with subcutaneous dalteparin sodium. Potassium chloride supplies potassium; sodium in the injection is a separate constituent, not the cause of this potassium-load interaction.
Read the interaction guide →Oral nutritional chromium supplements, mainly chromium picolinate in the cited trials; not industrial hexavalent chromium exposure.
Read the interaction guide →Metformin with an oral Aloe vera leaf-gel preparation; topical aloe, latex and other leaf extracts are outside the directly studied preparation.
Read the interaction guide →Hydrastis canadensis extract node: human evidence comes from a characterized product described both as root-extract capsules and dried root material. Whole-root follow-up evidence is indirect to an unspecified extract.
Read the interaction guide →Oral Hydrastis canadensis root products with metformin; whole root, characterized root capsules and purified berberine are not interchangeable.
Read the interaction guide →Oral metformin therapy and B12 status; assessment and replacement are distinct from an acute supplement interaction.
Read the interaction guide →Hypericum perforatum oral extracts; the direct report used a specific900mg/day preparation.
Read the interaction guide →Generic root/rhizome identity; confirm the valerian species.
Read the interaction guide →Piper methysticum preparations; beverages and extracts differ.
Read the interaction guide →Oral L-5-hydroxytryptophan supplements.
Read the interaction guide →Mitragyna speciosa leaf tea, powder or extracts; not interchangeable with isolated7-hydroxymitragynine or semisynthetic derivatives.
Read the interaction guide →Citrus paradisi fruit extract; direct evidence is from grapefruit juice, not standardized equivalence to this extract node.
Read the interaction guide →Oral Hypericum perforatum supplements with prescribed oral methamphetamine hydrochloride; product-specific risk size is unknown.
Read the interaction guide →Oral sodium bicarbonate used as an antacid or alkalinizing supplement; not a claim about incidental baking ingredients or emergency intravenous treatment.
Read the interaction guide →Camellia sinensis leaf extract; caffeine-containing, decaffeinated and brewed-tea preparations are not interchangeable.
Read the interaction guide →Citrus aurantium extracts; synephrine content is product-specific. No equivalence to isolated synephrine, ephedrine or ordinary fruit intake.
Read the interaction guide →Oral L-5-hydroxytryptophan, not L-tryptophan, another positional isomer or whole Griffonia seed at an assumed equivalent dose.
Read the interaction guide →Oral ascorbic acid supplements; buffered vitamin C salts, usual food intake and other acidifying agents are not assumed equivalent.
Read the interaction guide →Paullinia cupana seed preparations; assess measured caffeine and other ingredients rather than assuming all extracts are equivalent.
Read the interaction guide →Caffeine supplements with prescribed oral methamphetamine hydrochloride; severe overdose and experimental findings are not routine-dose estimates.
Read the interaction guide →Oral L-tryptophan supplements; the warning does not establish a need to restrict ordinary protein-containing foods or equate L-tryptophan with L-5-HTP.
Read the interaction guide →Ilex paraguariensis leaf tea or supplements; the inspected tea trial does not define concentrated extract exposure.
Read the interaction guide →Herba Ephedrae products containing ephedrine alkaloids; do not assume all species, plant parts or alkaloid-free products are equivalent.
Read the interaction guide →Applies to clinician-directed folic acid with low-dose weekly systemic methotrexate for inflammatory disease; folinic acid and rescue protocols are separate.
Read the interaction guide →Oral methylprednisolone with glycyrrhizin-containing Glycyrrhiza glabra root/stolon preparations. Deglycyrrhizinated products and uncharacterized extracts differ.
Read the interaction guide →Oral methylprednisolone used for immunosuppression and specified Echinacea purpurea fresh flowering aerial-part juice preparations. Root extracts, other species and topical products differ.
Read the interaction guide →Oral methylprednisolone with aluminum hydroxide. Relevant studies used particular antacid mixtures and other corticosteroids; elemental nutrient entries are not identical to antacid formulations.
Read the interaction guide →Adequate calcium intake during oral methylprednisolone treatment, especially prolonged systemic glucocorticoid exposure. Nutritional adequacy is not automatic need for a supplement or evidence of impaired tablet absorption.
Read the interaction guide →Potassium intake and replacement during oral methylprednisolone treatment. Monitoring and replacement depend on dose, indication, kidney function, other medicines and test results.
Read the interaction guide →Adequate vitamin D intake during oral methylprednisolone treatment, especially prolonged systemic glucocorticoid exposure. Nutritional adequacy is not automatic need for a supplement or evidence of impaired tablet absorption.
Read the interaction guide →Oral methylprednisolone with Radix et Rhizoma Glycyrrhizae products such as Gan cao. Species, processing, plant part and glycyrrhizin content require verification.
Read the interaction guide →Glycyrrhizin-containing oral licorice preparations with oral metolazone tablets. Defined root/stolon preparations are not every processed rhizome, formula or deglycyrrhizinated product.
Read the interaction guide →Oral Allium sativum products with metolazone; available evidence concerns a standardized aged bulb extract.
Read the interaction guide →Dietary sodium chloride and sodium status during oral metolazone treatment; blood sodium does not directly prescribe a salt-supplement dose.
Read the interaction guide →Oral Crataegus monogyna products with metolazone; unidentified hawthorn and C.laevigata evidence are adjacent only.
Read the interaction guide →Oral potassium intake and replacement during oral metolazone tablets treatment, distinguished from automatic supplementation or intravenous correction.
Read the interaction guide →Oral vitamin D products, particularly high doses, with metolazone; calcium status and underlying parathyroid disease matter.
Read the interaction guide →Glycyrrhizin-containing oral licorice preparations with oral metolazone tablets. Defined root/stolon preparations are not every processed rhizome, formula or deglycyrrhizinated product.
Read the interaction guide →Adult oral raltegravir tablets with calcium carbonate antacid. Direct studies used an antacid amount of 3,000 mg calcium carbonate; supplement doses, combination products and pediatric formulations cannot be assumed to have the same measured effect.
Read the interaction guide →Adult oral raltegravir tablets and oral iron supplements. Advice is based on potential polyvalent-mineral binding and exact-drug guidelines, not a retrieved isolated-iron pharmacokinetic or virologic outcome trial.
Read the interaction guide →Adult oral raltegravir tablets with magnesium-containing antacids or nutritional supplements. Direct trials tested magnesium hydroxide combined with aluminum hydroxide, not every magnesium glycinate, citrate or other stand-alone supplement.
Read the interaction guide →Adult oral raltegravir tablets and aluminum-containing antacids. Direct studies used aluminum hydroxide combined with magnesium hydroxide; isolated nutritional aluminum exposure and pediatric formulations were not separately studied.
Read the interaction guide →Adult oral raltegravir tablets with zinc-containing supplements. Exact zinc salts, repeated lozenge schedules and dose thresholds were not established in a retrieved raltegravir-zinc trial.
Read the interaction guide →Adult oral raltegravir tablets and calcium products. Direct studies used calcium carbonate antacid; nutritional calcium salts and mixtures require a separate assessment. Isentress 400 mg twice daily and Isentress HD 1,200 mg once daily remain distinct.
Read the interaction guide →Adult oral raltegravir tablets and multivitamin products. Direct neutral evidence concerns one Forceval capsule with a single Isentress 400 mg dose fasting; it does not establish equivalence for prenatal products, other mixtures or Isentress HD 1,200 mg once daily.
Read the interaction guide →Oral nadolol with the exact supplement preparation described below. Studied green-tea brews and aqueous EGCG-concentrated leaf extracts, not automatic equivalence with black tea or every capsule.
Read the interaction guide →Oral nadolol with the exact supplement preparation described below.
Read the interaction guide →Oral nadolol with the exact supplement preparation described below. Calcium carbonate, mixed salts and calcium-containing food are not interchangeable exposures.
Read the interaction guide →Oral nadolol with the exact supplement preparation described below.
Read the interaction guide →Oral nadolol with the exact supplement preparation described below. Studied green-tea brews and aqueous EGCG-concentrated leaf extracts, not automatic equivalence with black tea or every capsule.
Read the interaction guide →Oral nadolol with the exact supplement preparation described below.
Read the interaction guide →Oral nadolol with the exact supplement preparation described below.
Read the interaction guide →Oral Hypericum perforatum with amoxapine tablets; no assumed equivalence to other antidepressants.
Read the interaction guide →Radix et Rhizoma Valerianae species unresolved; V. officinalis evidence is conditional on confirmation.
Read the interaction guide →Oral Piper methysticum; extract, amount and other sedatives are relevant.
Read the interaction guide →Concentrated oral L-5-hydroxytryptophan, not L-tryptophan or whole Griffonia seed.
Read the interaction guide →Oral melatonin and amoxapine; prolonged-release melatonin studies with imipramine are indirect.
Read the interaction guide →Oral S-adenosyl-L-methionine, distinct from injected SAMe and ordinary methionine in food.
Read the interaction guide →Oral Valeriana officinalis root and rhizome products; mixtures and other species are not assumed equivalent.
Read the interaction guide →Oral 3,3′-diindolylmethane supplements, especially the absorption-enhanced formulation studied in small trials; I3C and ordinary vegetable intake are separate exposures.
Read the interaction guide →Withania somnifera products; the root-only trial does not establish equivalent effects for leaf extracts or mixed products.
Read the interaction guide →Oral Piper methysticum products; extraction method and composition vary.
Read the interaction guide →Oral indole-3-carbinol supplements studied at 400-800 mg daily; DIM supplements and ordinary cruciferous vegetables are different exposures.
Read the interaction guide →Purified oral prescription cannabidiol provides most of the evidence; nonprescription CBD formulations and other routes are not assumed equivalent.
Read the interaction guide →Specified oral Humulus lupulus hop-strobile preparations; combination sleep products, beer and isolated hop constituents are separate exposures.
Read the interaction guide →Paullinia cupana seed preparations containing caffeine; the actual amount depends on the product.
Read the interaction guide →Echinacea purpurea root and a separately studied E. purpurea extract; other species, plant parts and combination products are not equivalent.
Read the interaction guide →Caffeine intake during oral ropinirole treatment; advice about restless legs syndrome does not automatically apply to Parkinson disease.
Read the interaction guide →German chamomile flowering-top extract, with Matricaria recutita and Matricaria chamomilla identity supported by NCCIH; not Roman chamomile or an assumed tea-equivalent dose.
Read the interaction guide →Passiflora incarnata herb preparations, not fruit, another species or an assumed equivalent mixed product.
Read the interaction guide →Oral melatonin; licensed prolonged-release instructions and trial doses are preparation-specific.
Read the interaction guide →Oral Mucuna seed powders and extracts considered with immediate-release oral ropinirole. Evidence about prescription levodopa, selected seed preparations and commercial products is kept distinct; Parkinson-disease trials do not establish a treatment for restless legs syndrome.
Read the interaction guide →Pausinystalia johimbe products used alongside immediate-release oral ropinirole. Studies of measured pharmaceutical yohimbine are indirect for a whole-bark product or an extract with an unknown alkaloid amount.
Read the interaction guide →HPUS-labelled Rauwolfia serpentina preparations. One oral 6X-and-higher liquid is an identification example, not a match to every potency or product.
Read the interaction guide →Characterized oral THC/CBD cannabis extracts. Hempseed foods, cannabinoid-free preparations, isolated CBD and smoke exposure are distinct.
Read the interaction guide →Generic synephrine with immediate-release oral ropinirole. Human studies cited here used specified p-synephrine/bitter-orange products; they do not authenticate every product labeled synephrine or establish the effects of different stimulants.
Read the interaction guide →Oral L-arginine supplements. High-dose intravenous findings are not treated as equivalent to oral use.
Read the interaction guide →Oral iron preparations with oral risedronate sodium. Intravenous iron is outside the intestinal co-administration concern assessed here.
Read the interaction guide →Oral magnesium-containing supplements, antacids or laxatives with oral risedronate. Equal effects for every magnesium salt or for non-oral magnesium have not been established.
Read the interaction guide →Oral aluminum-containing antacids or other medicinal products with oral risedronate. This is not a general warning about environmental aluminum, food or topical exposure.
Read the interaction guide →Oral zinc-containing supplements with oral risedronate. The inference concerns supplemental mineral exposure, not all food, topical zinc or every chemical form.
Read the interaction guide →Oral calcium supplements with immediate-release or delayed-release oral risedronate sodium. Adequate total calcium intake and separation of a supplement dose are separate decisions.
Read the interaction guide →Vitamin D intake or oral supplementation during oral risedronate therapy. Plain vitamin D and calcium-vitamin D products are distinguished; exact D2 and D3 dose equivalence is not established here.
Read the interaction guide →Oral multivitamin products with oral risedronate, conditional on mineral content and medication formulation. A multivitamin is not a single chemically uniform ingredient.
Read the interaction guide →Applies to oral norethindrone 0.35 mg progestin-only contraceptive tablets; combination pills, norethindrone acetate and other indications are distinct.
Read the interaction guide →Oral Hypericum perforatum. An amitriptyline metabolite study is indirect for prescribed nortriptyline.
Read the interaction guide →Panax ginseng preparations, with Korean red Rg3-enriched extract distinct from other products or species.
Read the interaction guide →Radix et Rhizoma Valerianae species unresolved; V. officinalis evidence is conditional on confirmation.
Read the interaction guide →Citrus aurantium oral extract, not ordinary food portions, topical oil or every isolated synephrine product.
Read the interaction guide →Concentrated oral L-5-hydroxytryptophan, distinct from tryptophan and whole seed preparations.
Read the interaction guide →Oral melatonin product added to nortriptyline with other centrally active medicines.
Read the interaction guide →Oral S-adenosyl-L-methionine supplementation, distinct from injected regimens and ordinary dietary methionine.
Read the interaction guide →Supplemental oral L-tryptophan, not dietary protein or L-5-HTP.
Read the interaction guide →Oral ofloxacin tablets and oral iron products; direct study tested ferrous sulfate. Intravenous iron and nonoral antibiotic use are outside this gut-absorption finding.
Read the interaction guide →Oral ofloxacin tablets with magnesium-containing antacids. Direct study used a combined magnesium/aluminum hydroxide preparation; eye and ear drops are outside this absorption finding.
Read the interaction guide →Oral ofloxacin tablets with aluminum-containing antacids. Direct study used a combined magnesium/aluminum hydroxide preparation; eye and ear drops are outside this absorption finding.
Read the interaction guide →Oral ofloxacin tablets and oral zinc products, including zinc-containing multivitamins. No quantified equivalence across zinc salts or antibiotic routes.
Read the interaction guide →Oral ofloxacin and calcium-containing antacids; separate discussion of dietary milk. Direct evidence does not establish simultaneous calcium-supplement safety or equal effects for every salt.
Read the interaction guide →Oral ofloxacin and mineral-containing multivitamins; exact ingredients retained. No claim of equal interaction for all multivitamin brands or vitamin-only formulations.
Read the interaction guide →Oral quercetin supplements with omeprazole; ginkgo mixtures, quercetin glycosides and different drug probes are not interchangeable evidence.
Read the interaction guide →Oral Hypericum perforatum tablets or supplements with oral omeprazole; effects of the tested botanical regimen do not establish every product’s magnitude.
Read the interaction guide →Long-term oral omeprazole and magnesium status/replacement, not an acute binding interaction between two doses.
Read the interaction guide →Oral omeprazole and protein-bound dietary B12/status; free oral supplements and injections were not tested in the short absorption study.
Read the interaction guide →Oral omeprazole and calcium intake/status; specific supplement salt, meal conditions, skeletal risk and magnesium-related hypocalcemia remain separate.
Read the interaction guide →Oral Hypericum perforatum extracts with oxazepam; CYP3A probe findings and glucuronide metabolism are distinct.
Read the interaction guide →Unresolved Radix et Rhizoma Valerianae species; V. officinalis guidance and LI 156 extract evidence apply only to matched products.
Read the interaction guide →Oral Withania somnifera; root-extract sleep findings are not equivalent to all leaves, extracts or mixtures.
Read the interaction guide →Oral Camellia sinensis leaf extract; caffeine, catechins, brewed tea and decaffeinated products are distinct exposures.
Read the interaction guide →Oral Piper methysticum; medicinal extract/cultivar doses are distinct from recreational quantities or mixtures.
Read the interaction guide →Oral Humulus lupulus female inflorescence preparations; other plant parts or mixtures are not equivalent.
Read the interaction guide →Oral Passiflora incarnata extract/aerial-part preparations; not other species or unidentified mixtures.
Read the interaction guide →Oral Melissa officinalis leaf preparations; other plant parts or mixtures are not equivalent.
Read the interaction guide →Oral Hypericum perforatum preparations; product composition varies, and tapentadol is not primarily CYP-cleared.
Read the interaction guide →Generic root/rhizome node; Valeriana officinalis evidence applies only when that species/preparation is confirmed.
Read the interaction guide →Piper methysticum beverages and extracts.
Read the interaction guide →Oral L-5-HTP supplement, not food-level tryptophan.
Read the interaction guide →Passiflora incarnata herb preparations; not all passionflower species or mixtures.
Read the interaction guide →Oral melatonin products with variable dose and release form.
Read the interaction guide →Oral S-adenosylmethionine supplements; dose and formulation vary.
Read the interaction guide →Supplemental L-tryptophan, not ordinary protein-containing foods.
Read the interaction guide →Oral willow bark products with oral extended-release pentoxifylline. Exact formulation and clinical setting matter; aspirin, warfarin and other medicines are not interchangeable.
Read the interaction guide →Oral vitamin E supplements with oral extended-release pentoxifylline. Supervised post-radiation regimens, food intake and other high-dose supplement uses are distinct.
Read the interaction guide →Oral garlic supplements products with oral extended-release pentoxifylline. Exact formulation and clinical setting matter; aspirin, warfarin and other medicines are not interchangeable.
Read the interaction guide →Oral policosanol products with oral extended-release pentoxifylline. Exact formulation and clinical setting matter; aspirin, warfarin and other medicines are not interchangeable.
Read the interaction guide →Oral Paullinia cupana seed products containing caffeine; whole plant, extracts and mixtures are not interchangeable. Exact oral extended-release pentoxifylline treatment.
Read the interaction guide →Oral chondroitin sulfate products with oral extended-release pentoxifylline. Exact formulation and clinical setting matter; aspirin, warfarin and other medicines are not interchangeable.
Read the interaction guide →Oral caffeine from supplements or drinks; dose and timing vary. Exact oral extended-release pentoxifylline treatment.
Read the interaction guide →Oral Ginkgo biloba products with oral extended-release pentoxifylline. Exact formulation and clinical setting matter; aspirin, warfarin and other medicines are not interchangeable.
Read the interaction guide →Oral Ganoderma products products with oral extended-release pentoxifylline. Exact formulation and clinical setting matter; aspirin, warfarin and other medicines are not interchangeable.
Read the interaction guide →Oral perphenazine with the exact supplement preparation described.
Read the interaction guide →Oral perphenazine with the exact supplement preparation described.
Read the interaction guide →Oral perphenazine with the exact supplement preparation described.
Read the interaction guide →Oral perphenazine with the exact supplement preparation described.
Read the interaction guide →Oral perphenazine with the exact supplement preparation described.
Read the interaction guide →Oral perphenazine with the exact supplement preparation described.
Read the interaction guide →Oral Cytisus scoparius preparations that contain tyramine, particularly the aerial or flowering material described in the source. Plant part and preparation are essential; other broom species and purified constituents are not interchangeable.
Read the interaction guide →Oral Hypericum perforatum preparations used for mood symptoms with oral MAOI treatment. Other botanical species, topical preparations and specific extract strengths are not assumed to be equivalent.
Read the interaction guide →Camellia Sinensis Leaf Extract, taken orally; the extraction method and caffeine content matter. This does not cover topical tea preparations.
Read the interaction guide →Oral Citrus aurantium fruit extracts containing p-synephrine or other adrenergic constituents, especially stimulant blends. This does not cover ordinary food portions, aromatic oils, skin use or synthetic m-synephrine.
Read the interaction guide →Oral L-tyrosine supplements with phenelzine tablets. This is not a recommendation to eliminate ordinary protein foods; the medication's separate food guidance still applies.
Read the interaction guide →Oral L-5-hydroxytryptophan supplements with oral phenelzine. This does not equate 5-HTP with L-tryptophan or every botanical product containing a precursor.
Read the interaction guide →Oral Paullinia cupana seed preparations that contain caffeine. No assumption is made about the caffeine concentration of an unidentified brand, a different plant part or a caffeine-free preparation.
Read the interaction guide →Oral phenelzine tablets with caffeine from drinks, tablets, powders or other supplements. The concern depends on total exposure; no universal safe amount has been established for this combination.
Read the interaction guide →Oral Ephedra sinica stem or above-ground preparations containing ephedrine-type alkaloids. The assessment does not equate root preparations, other species, purified ephedrine products or unverified alkaloid-free products.
Read the interaction guide →Oral yohimbine as the selected compound with oral phenelzine. Yohimbe bark is not treated as an interchangeable dose or composition, and alpha-yohimbine/rauwolscine is not automatically included.
Read the interaction guide →Supplemental oral L-tryptophan with phenelzine tablets. This is not a blanket prohibition on normal protein-containing foods and does not substitute 5-HTP for tryptophan.
Read the interaction guide →Oral L-phenylalanine supplements with phenelzine tablets. This is not a recommendation to eliminate ordinary protein foods; the medication's separate food guidance still applies.
Read the interaction guide →Vitamin B6 status during oral phenelzine treatment. The reported corrective treatment was pyridoxine; other B6 forms and preventive regimens are not assumed to have equivalent evidence.
Read the interaction guide →Oral Valeriana officinalis preparations; not another Valeriana species or an unidentified root mixture.
Read the interaction guide →Oral Angelica sinensis products; no assumption that other Angelica species or isolated constituents behave identically.
Read the interaction guide →Radix et Rhizoma Valerianae has unresolved species identity; V. officinalis guidance applies only if that species is confirmed.
Read the interaction guide →Oral Withania somnifera; the cited sleep trial used a specific root extract, not all leaf/root preparations.
Read the interaction guide →Oral Piper methysticum products; exact extract, dose and co-ingredients matter.
Read the interaction guide →Oral Passiflora incarnata aerial-part preparations matching the monograph; other species or extracts may differ.
Read the interaction guide →Vitamin D2/D3 nutrition during long-term oral treatment; no inference that every user is deficient.
Read the interaction guide →Exact folic acid replacement; dietary folate, folinic acid and methylfolate are distinct exposures.
Read the interaction guide →Evidence concerns supplemental pyridoxine, particularly 200 mg/day exposures; not all B6 vitamers, foods or ordinary nutritional intake.
Read the interaction guide →Oral phenylephrine hydrochloride with Camellia sinensis leaf extract. Extracts vary in caffeine and catechin content; brewed tea and isolated EGCG are not interchangeable. Rat tissue and intravenous extract studies do not establish human oral effects.
Read the interaction guide →Oral phenylephrine hydrochloride with Citrus aurantium fruit or peel supplements. Natural p-synephrine is distinct from phenylephrine, also called m-synephrine. Food flavorings and topical oils are outside the concentrated oral-extract assessment.
Read the interaction guide →Oral phenylephrine hydrochloride with Paullinia cupana, usually a guarana seed preparation. Evidence about purified caffeine or a mixed weight-loss product is indirect for a specific guarana supplement; nonoral phenylephrine is outside this assessment.
Read the interaction guide →Oral phenylephrine hydrochloride and caffeine. The strongest practical guidance is for one finished product containing phenylephrine, caffeine and paracetamol. A research gel used under the tongue is a different preparation; nasal sprays, eye drops and injections are outside this advice.
Read the interaction guide →Oral phenylephrine hydrochloride with yohimbe bark supplements, represented in the dataset as Pausinystalia johimbe. Sources commonly use Pausinystalia yohimbe. Purified yohimbine studies are indirect; injected phenylephrine experiments do not establish oral supplement interactions.
Read the interaction guide →Oral phenylephrine hydrochloride with Coffea arabica seed extract. Government evidence includes green coffee from several Coffea species; applicability is limited to the actual product and its caffeine content. Brewed coffee is a separate exposure.
Read the interaction guide →Oral phenylephrine hydrochloride with Ilex paraguariensis leaf preparations. Brewed mate, concentrated extracts and mixed energy products are different exposures. The inspected mouse study used injected phenylephrine as a separate comparator.
Read the interaction guide →Oral phenylephrine hydrochloride and Rhodiola rosea supplements. Findings for a particular commercial rhodiola extract or other medicines do not automatically apply to this pair. Nasal, eye and injected phenylephrine require separate assessment.
Read the interaction guide →Oral phenylephrine hydrochloride and Radix et Rhizoma Glycyrrhizae, the licorice root/rhizome ingredient. Evidence is relevant chiefly to glycyrrhizin-containing oral preparations; species and processing may vary. DGL and topical licorice are distinct exposures.
Read the interaction guide →Oral Hypericum perforatum preparations with oral phenytoin; induction strength varies across products.
Read the interaction guide →Convolvulus prostratus, including research under its scientific synonym C. pluricaulis, with phenytoin; a named Ayurvedic mixture is not automatically equivalent.
Read the interaction guide →Oral magnesium products with oral phenytoin; antacid salts, nutritional preparations and intravenous treatment differ.
Read the interaction guide →Lepidium sativum preparations with oral phenytoin; tested animal exposure does not establish effects of ordinary food or all extracts.
Read the interaction guide →Ginkgo leaf products with phenytoin; seed poisoning and multicomponent exposures do not establish the effect of every leaf extract.
Read the interaction guide →Piper nigrum products with oral phenytoin; purified piperine, pepper-containing food and commercial extracts have different exposures.
Read the interaction guide →Oral calcium products with oral phenytoin; antacid salts, nutritional preparations and intravenous treatment differ.
Read the interaction guide →Folic acid with oral phenytoin; folate status, pregnancy needs, formulation and individual seizure control matter.
Read the interaction guide →Oral vitamin B6, particularly high-dose pyridoxine, with phenytoin; different vitamers and nutritional amounts are not assumed equivalent.
Read the interaction guide →Applies to amphetamine sulfate with St. John's wort products; the risk concerns overlapping effects on serotonin.
Read the interaction guide →Applies to oral amphetamine sulfate during sodium bicarbonate use that meaningfully reduces gastrointestinal or urinary acidity.
Read the interaction guide →Applies to sodium phosphate, monobasic, identified in the source as sodium acid phosphate, with oral amphetamine sulfate during meaningful urinary acidification.
Read the interaction guide →Applies to oral amphetamine sulfate and antacids that meaningfully reduce acidity; other heartburn medicines and mineral preparations are not interchangeable.
Read the interaction guide →Applies to concentrated L-tryptophan supplementation with systemic amphetamine sulfate; the record does not establish the same risk from ordinary dietary protein.
Read the interaction guide →Oral levofloxacin tablets with oral iron products. The directly inspected trial tested ferrous sulfate; injected iron and other antibiotic routes are not assessed by this absorption evidence.
Read the interaction guide →Oral levofloxacin tablets with magnesium oxide or magnesium-containing antacid products. Other nutritional salts require product-specific applicability; low blood magnesium is a separate issue.
Read the interaction guide →Oral levofloxacin tablets and aluminum-containing oral antacids. The direct trial used aluminum hydroxide; dietary traces, skin products and injected treatment are outside that finding.
Read the interaction guide →Oral levofloxacin tablets with zinc salts, zinc supplements or zinc-containing multivitamins. Nonoral zinc and racemic ofloxacin are outside this specific assessment.
Read the interaction guide →Oral levofloxacin with calcium carbonate; cystic-fibrosis findings are a distinct subgroup. Calcium-fortified juice is discussed as an indirect food comparison, not as a pure calcium supplement.
Read the interaction guide →Oral levofloxacin tablets with mineral-containing multivitamins, including prenatal products when their ingredients match the label warning. Vitamin-only preparations are not automatically included.
Read the interaction guide →Oral pindolol with the exact supplement preparation described below.
Read the interaction guide →Oral pindolol with the exact supplement preparation described below.
Read the interaction guide →Oral pindolol with the exact supplement preparation described below.
Read the interaction guide →Oral pindolol with the exact supplement preparation described below.
Read the interaction guide →Oral pindolol with the exact supplement preparation described below. Calcium carbonate, mixed salts and calcium-containing food are not interchangeable exposures.
Read the interaction guide →Oral pindolol with the exact supplement preparation described below.
Read the interaction guide →Oral pindolol with the exact supplement preparation described below.
Read the interaction guide →Oral pindolol with the exact supplement preparation described below.
Read the interaction guide →Oral pindolol with the exact supplement preparation described below.
Read the interaction guide →Applies to oral atorvastatin; the direct study tested one St. John's wort product for four weeks, and extract potency can vary.
Read the interaction guide →Panax ginseng, the Asian ginseng node, with oral atorvastatin. Siberian ginseng, other species and mixed supplements are excluded as exact matches.
Read the interaction guide →Oral red yeast rice supplements with atorvastatin. Monacolin content and additional ingredients determine how closely a studied product matches a bottle.
Read the interaction guide →Oral atorvastatin and Avena sativa oat bran. Ordinary oat foods, concentrated bran and other fibers are not treated as identical exposures.
Read the interaction guide →The direct study involved oral atorvastatin and vitamin D 800 IU daily for six weeks in 16 adults.
Read the interaction guide →Oral atorvastatin and Citrus paradisi juice. Concentrated botanical supplements and other statins need separate assessment.
Read the interaction guide →Oral Camellia sinensis products; strongest direct evidence is for dry extract capsules taken with a single atorvastatin dose.
Read the interaction guide →Oral pectin supplements with oral atorvastatin. Dietary fruit, other fiber products and experimental drug-delivery formulations are outside this exact-pair assessment.
Read the interaction guide →Oral atorvastatin with niacin-containing products. Nicotinic acid, niacinamide and nutritional amounts require distinct interpretation.
Read the interaction guide →Oral prazosin with glycyrrhizin-containing Glycyrrhiza glabra root or stolon products. Deglycyrrhizinated licorice and other plant parts are not assumed equivalent.
Read the interaction guide →Oral prazosin with Ruscus aculeatus, with regulatory evidence restricted to specified rhizome preparations.
Read the interaction guide →Oral prazosin with Allium sativum supplements. The human evidence concerns a specific aged bulb extract, not ordinary food portions or every garlic oil or powder.
Read the interaction guide →Oral prazosin and Piper methysticum products; medicinal kava extracts differ from recreational beverages and high doses.
Read the interaction guide →Oral prazosin and Crataegus monogyna. Human hawthorn studies used an incompletely authenticated leaf-and-flower extract or C.laevigata, a different species.
Read the interaction guide →Oral prazosin with Pausinystalia johimbe bark products. Yohimbine tablets provide constituent evidence and are not dose-equivalent to an unspecified botanical.
Read the interaction guide →Oral prazosin and supplemental L-arginine; oral gram-dose studies, not IV arginine or dietary protein.
Read the interaction guide →Oral Valeriana officinalis preparations; not another Valeriana species or an unidentified root mixture.
Read the interaction guide →Oral Angelica sinensis products; no assumption that other Angelica species or isolated constituents behave identically.
Read the interaction guide →Hypericum perforatum preparations with oral primidone; not assumed equivalent to phenobarbital-only treatment.
Read the interaction guide →Exact nicotinamide/niacinamide; not interchangeable with nicotinic acid or dietary vitamin B3 exposure.
Read the interaction guide →Oral Piper methysticum products; exact extract, dose and co-ingredients matter.
Read the interaction guide →Folate is the nutrient category; specific treatment evidence concerns folic acid, not automatic equivalence to folinic acid or methylfolate.
Read the interaction guide →Dietary or supplemental calcium during long-term oral primidone; not calcium-channel pharmacology or product excipients.
Read the interaction guide →Vitamin D2/D3 nutrition during long-term oral treatment; no inference that every user is deficient.
Read the interaction guide →Vitamin K1/phytomenadione around pregnancy and delivery; maternal oral treatment is distinct from newborn prophylaxis, vitamin K2 and routine adult supplementation.
Read the interaction guide →Oral prochlorperazine with the exact supplement preparation described.
Read the interaction guide →Oral prochlorperazine with the exact supplement preparation described.
Read the interaction guide →Oral prochlorperazine with the exact supplement preparation described.
Read the interaction guide →Oral prochlorperazine with the exact supplement preparation described.
Read the interaction guide →Oral prochlorperazine with the exact supplement preparation described.
Read the interaction guide →Oral prochlorperazine with the exact supplement preparation described.
Read the interaction guide →Oral promethazine with the specific preparation described below.
Read the interaction guide →Oral promethazine with the specific preparation described below.
Read the interaction guide →Oral promethazine with the specific preparation described below.
Read the interaction guide →Oral promethazine with the specific preparation described below.
Read the interaction guide →Oral promethazine with the specific preparation described below.
Read the interaction guide →Oral promethazine with the specific preparation described below.
Read the interaction guide →Oral promethazine with the specific preparation described below.
Read the interaction guide →Oral promethazine with the specific preparation described below.
Read the interaction guide →Oral Hypericum perforatum with protriptyline hydrochloride tablets.
Read the interaction guide →Panax ginseng; separate energy drinks and Rg3-enriched Korean red extracts are distinct exposures.
Read the interaction guide →Radix et Rhizoma Valerianae species unresolved; V. officinalis evidence is conditional on confirmation.
Read the interaction guide →Oral Piper methysticum extract; different blends and other sedatives require separate review.
Read the interaction guide →Oral Passiflora incarnata herb, not fruit or other species.
Read the interaction guide →Oral S-adenosylmethionine supplement; not ordinary dietary nutrients.
Read the interaction guide →Oral sotalol with the exact supplement preparation described below.
Read the interaction guide →Oral sotalol with the exact supplement preparation described below.
Read the interaction guide →Oral sotalol with the exact supplement preparation described below.
Read the interaction guide →Oral sotalol with the exact supplement preparation described below.
Read the interaction guide →Oral sotalol with the exact supplement preparation described below.
Read the interaction guide →Oral sotalol with the exact supplement preparation described below.
Read the interaction guide →Oral sotalol with the exact supplement preparation described below.
Read the interaction guide →A supplement missing from this list has not been cleared for use with the medication. These pages do not assess every product, formulation, or combination.
Publication status, clinical review and change history are shown in each interaction guide.